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Abstract
DETERMINATION OF STRUCTURE OF HEPATITIS B VIRUS E ANTIGEN
By
Asheel Patel, Bachelors in Pharmacy
A thesis submitted in partial fulfillment of the requirements for the degree of Masters 
of Science at Virginia Commonwealth University
Major Director: Dr. Darrell Peterson
Professor, Department of Biochemistry
Virginia Commonwealth University, 2010
Hepatitis  B virus  is a member of the hepadnavirus family. The hepatitis B virus 
core gene codes for two proteins viz. core protein and pre-core protein. These proteins 
assemble to form particles viz. HBcAg and HBeAg respectively. The structure of the 
HBcAg has been widely studied but very little is known about the structure of HBeAg. 
Therefore, the aim of this study was  to identify the disulfide bonding patterns in HBeAg. 
Recombinant HBeAg was isolated from E.coli and used for this  study along with various 
mutants  of HBeAg. There are four cysteines present in HBeAg each at position -7, 48, 
61 and 107. From this study it can be inferred that the cysteine at 61 and 48 were found 
to be involved in inter-molecular disulfide bonds  between the cysteine at 61 and 48 of 
other identical monomers. These di-mers were further inter-molecularly linked with 
cysteine at -7 to form chains. Moreover, the cysteine at -7 and cysteine at 107 were 
sometimes involved in intra-molecular disulfide bond formation. Thus, the HBeAg in a 
solution was found be particulate with a heterogeneous pattern of inter chain disulfide 
bonds.
ix
Chapter 1: Introduction
Hepatitis
Hepatitis  is a disease caused by a group of viruses that include Hepatitis A, B, C, 
D and E. Hepatitis can also be caused by toxins  such as alcohol, plants  or some 
medicines. This  disease causes inflammation of the liver. The most common viral 
infections in the United States are hepatitis  A, hepatitis B, hepatitis C and hepatitis D. 
Vaccines for Hepatitis  A and B are available but there is no vaccine yet available for 
hepatitis  C. The disease can be acute if it lasts  for less then 6 months or chronic if it 
persists longer then 6 months. The hepatitis  A and E cause acute diseases and are 
transmitted enterically, whereas hepatitis B, C and D viruses may produce chronic 
diseases and are transmitted via the blood (10). The symptoms of acute viral hepatitis 
are myalgia, vomiting, nausea, fatigue, a change in the sense of taste and smell, right 
upper abdominal pain, headache and diarrhoea which may have pale stools or dark 
urine (11).  Chronic hepatitis develops gradually without causing any obvious symptoms 
in two thirds of people. In the remaining one third, it is caused due to persistent acute 
hepatitis  or because of its  return. Symptoms often observed are malaise, fatigue and 
poor appetite (12).
Hepatitis B Virus (HBV)
Hepatitis  B is caused by hepatitis B virus. The hepatitis  B virus (HBV) is a 
member of the hepadnavirus family. There are two types of hepadnaviruses: 
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• The mammalian hepadnaviruses include the human hepatitis B virus, 
woodchuck hepatitis B virus and ground squirrel hepatitis B virus
• The avian hepadnaviruses include the duck hepatitis  B virus, heron hepatitis 
B virus and goose hepatitis B virus
Hepadnaviruses are widespread in nature. Although there are only a few known 
hepadnaviruses, there are probably many others in nature yet to be discovered.
Figure 1. Hepatitis B Virus geographical distribution (14)
The hepatitis B Virus is  divided into 8 genotypes (A - H). These genotypes have 
distinct geographical distribution. Moreover, different genotypes cause differences in the 
severity of the infection and may respond to treatment in different ways. Type A 
genotype has two subtypes viz. Type A(A1) and type A(A2). The A(A1) subtype is 
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prevalent in Africa/Asia and Philippines, whereas the A(A2) subtype is  prevalent in 
Europe/United States. The Type B genotype has two subtypes viz. Bj/B1 and Ba/B2. 
The ‘j’ for subtype Bj/B1 stands for Japan and the ‘a’ for subtype Ba/B2 stands for Asia. 
Moreover, Type C genotype is divided in two subtypes viz. Cs/C1 and Ce/C2. The Cs/
C1 subtype is prevalent in South-east Asia whereas  the Ce/C2 subtype is  prevalent in 
east Asia. The Type D genotype is  present in the Mediterranean area, Middle East and 
India. It is divided into 7 subtypes (D1 - D7). The Type E genotype is found in sub-
Saharan Africa. Type F and Type H are only found in Central and South America. The 
Type G genotype is  present in France and Germany. The genotypes  A, D and F are 
prevalent specifically in Brazil and all the genotypes  are present in United States 
depending on the ethnicity of the area (13).
Hepatitis B Virus Structure
Figure 2. The Dane particle (15)
The hepatitis B virus is  42nm in size and is a double-shelled particle that was 
originally called the Dane particle (15). It consists of a 7nm thick outer shell and a 27nm 
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inner core.  The core contains a DNA polymerase along with a small, circular, partially 
double-stranded DNA (9).
The hepatitis  B virus surface protein (HBs) is  associated with complex antigenic 
determinants present on the surface of HBV. These have a particle size of 22nm and 
are spherical or tubular in shape (9). The HBc is a major structural component of the 
HBV viral nucleocapsid and is  27nm in size. The woodchuck hepatitis virus also has a 
similar protein whereas the duck hepatitis virus has  an analogous protein. It has been 
shown recently that the deletion of 39 amino acids at the carboxyl terminus of the HBc 
results in the formation of a truncated HBc that still has the capability of forming core 
particles. However, the truncated HBc no longer had the ability to bind nucleic acids (3, 
4, 5).
The pre-core is closely related to the nucleocapsid of HBV. It is a 25 kDa protein. 
It is N-terminally as well as C-terminally processed and is secreted as non-particulate E 
antigen (HBeAg). The pre-core protein has extra 29 N-terminal amino acids. These N-
terminal amino acids serve as a signal peptide which directs the nascent polypeptide 
chain into the secretory pathway. The signal sequence is cleaved during translocation 
into the lumen of the endoplasmic reticulum thus generating a 22 kDa protein. This 22 
kDa mature HBeAg is C-terminally truncated at amino acid 149 of HBc and retains only 
10 amino acids out of the 29 original pre-core amino acids  at the N-terminal, thus 
generating a 17 kDa protein which is called the HBeAg (6, 16, 17, 18, 19).
The HBeAg was first found by Magnius and Espmark in 1972 (25). It was then 
shown to be closely associated with the hepatitis B Virus core. The HBeAg was found in 
sera with the presence of Dane particles (Nordenfelt and Kjellen, 1975 and Takahashi et 
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al. 1976). It was  observed that the HBeAg in serum can be associated with high 
infectivity (Magnius et al. 1975 and Okada et al. 1976) and it may be a prognostic value 
in predicting the course of liver disease (Trepo et al, 1976) (20). It was  also observed 
that the HBeAg and the Dane particles had an intimate relationship and the HBeAg 
demonstrated a signal of high infectivity for transmission of HBV (23). The HBeAg was 
found to be a homogenous mixture of particles ranging from molecular weight of 200000 
to 300000 daltons. It was previously stated that this large molecules  were formed 
because of interaction of the IgG with HBeAg (21, 22). But in 1979 it was characterized 
as an antigenic protein containing determinant borne out of the core protein of the HBV 
(26). This was further proven by the generation of HBeAg determinants by proteolytic 
digestion of HBV core expressed in E.coli (20). It has also been stated that HBeAg is a 
degradation product of HBcAg and this is the reason why HBeAg and not HBcAg is 
found in the serum of infected patients. The HBeAg is present with free HBV DNA in 
plasma as well as  liver and thus can be used as an diagnostic marker. The HBV DNA is 
in free state because the DNA binding region at the C-terminal of HBcAg is not available 
in HBeAg (20). Moreover, three antigenic determinants were characterized. The single 
conformational determinant responsible for HBc antigenicity in assembled core and a 
linear HBe related determinant (HBe1) were both found overlapping near the amino acid 
80 region. The second determinant  (HBe2) was assigned to location around amino acid 
138 but to become antigenic, it required the intra-molecular participation of the 
sequence between amino acids 10 and 140. It has been postulated that the HBcAg and 
HBeAg have common basic 3D structure which exposes the HBe1 determinant but they 
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differ in the two conformational determinant that are introduced (HBc) or is masked 
(HBe2) in the core (27).
Hepatitis B Virus Genome
  Figure 3. The Genome of Hepatitis B Virus
 The HBV genome consists  of a circular double-stranded DNA. This DNA 
replicates by a novel reverse transcription process. These viruses have a nucleocapsid 
which is the major structure of the virus. The nucleocapsid contains  genomic DNA, a 
core structural protein (HBc) and a reverse transcriptase. Moreover, the genome of HBV 
contains 4 open reading frames (ORFs). Various forms of surface proteins are encoded 
by the first ORF. Translation is  initiated by three in-frame methionine codons and this 
results in the formation of the Pre S1, Pre S2 and the HBs (1).
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The HBV core gene (second ORF) codes for two distinct proteins: a 21.5 kDa 
protein that assembles to form nucleocapsid particle (HBc) and a pre-core protein that is 
directed to the endoplasmic reticulum. Therefore, the HBV gene contains two in-phase 
initiation codons. Translation from the second ATG codon results in the expression of 
HBc whereas translation from the first ATG codon results in the synthesis of the pre-
core protein (1, 5). The third ORF is  the largest and it overlaps all the other ORFs. This 
ORF encodes for the viral DNA polymerase (1). The fourth ORF is  named as the ‘X’ 
since the function of this  gene was not known. It encodes for the HBx which is known to 
be a transcriptional transactivator. It was later suggested that HBx plays a role in the 
development of liver cancer by stimulating genes for cell growth and by inactivating 
growth regulatory molecules (1, 2).
The aim of this  project was to study the structure of HBeAg, and specifically to 
determine the disulfide bonding patterns in HBeAg. Therefore, we are only concerned 
with HBc and pre-core protein since this amino acid sequence ultimately gives rise to 
HBeAg. 
The following is the sequence of HBcAg:
   1 mdidpykefg asvellsflp sdffpsirdl ldtasalyrealespehcsp hhtalrqail
   
  61 cwgelmnlat wvgsnledpa srelvvsyvn vnmglkirql lwfhiscltf gretvleylv
  
 121 sfgvwirtpp ayrpqnapil stlpettvvr rrgrsprrrt psprrrrsqs prrrrsqsre
 
 181 pqc
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The following is the sequence of the Pre-core:
   1 mqlfhlclii sctcptvqas klclgwlwgm didpykefga tvellsflps dffpsvrdll
  61 dtasalyrea lespehcsph htalrqailc wgelmtlatw vgnnledpas rdlvvnyvnt
 121 nmglkirqll wfhiscltfg retvleylvs fgvwirtppa yrppnapils tlpettvvrr
 181 rdrgrsprrr tpsprrrrsq sprrrrsqsr esqc
The amino acids marked in red, in the above core and pre-core sequences, are 
not present in the final HBeAg sequence. Moreover, the pre-core sequence has an extra 
29 amino acids at the N-terminal of the core protein. These extra 29 amino acids are 
processed in the endoplasmic reticulum to give the HBeAg. The HBeAg sequence 
remains with only 10 amino acids at the N-terminal after being processed. These 10 
amino acids are marked in blue in the following HBeAg sequence. The molecular weight 
of HBeAg is 17 kilodaltons.
The following is the sequence of the HBeAg:
  1  SKLCLGWLWG MDIDPYKEFG ATVELLSFLP SDFFPSVRDL LDTASALYRE 
 
 51  ALESPEHCSP HHTALRQAIL CWGELMTLAT WVGVNLEDPA SRDLVVSYVN 
 
101  TNMGLKFRQL LWFHISCLTF GRETVIEYLV SFGVWIRTPP AYRPPNAPIL 
 
151  STLPETTVV
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Chapter 2: Background
The structure of HBcAg has been well studied but the structure of the HBeAg is 
not very well characterized. Even though the core and the pre-core have mostly 
identical sequences, they have different disulfide bonding patterns. So far, the following 
research work has been carried out on HBc and HBe.
The disulfide bonding pattern of the hepadnaviral core antigens  has been 
determined by Jian Zheng, Florian Schodel and Darrell Peterson. A set of wild type and 
mutant human, woodchuck and duck hepatitis  viral core proteins were prepared to study 
the free sulfhydryl groups and also to study disulfide bond formation within the core 
particles of different species. From their study, they stated that human and woodchuck 
core proteins contain 4 cysteine residues, whereas the duck core protein contained a 
single cysteine residue. Moreover, all the viral core proteins assemble into identical core 
particles and it was observed that disulfide bonds were not essential for core particle 
formation. They also found that no intra-chain disulfide bonds occured. Further, Cys107 
was a free thiol buried within the particle structure, whereas, Cys48 was present partly 
as a free sulfhydryl which was exposed at the surface of the particle. Cys61 was always 
involved in inter-chain disulfide bonds with the identical residues of another monomer 
whereas, Cys48 was partly involved in making inter-chain disulfide bonds with the 
identical residues with the same other monomer bound by Cys61. Cys183 was always 
involved in a disulfide bond with the Cys183 of a different monomer than Cys61 and 
Cys48. As a result of this disulfide bonding pattern, the HBcAg exists as a highly cross-
linked structure that will not even enter a normal SDS polyacrylamide gel under non-
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reducing conditions. The woodchuck core protein had the same pattern of bonding, 
whereas the duck core protein had no disulfide bonds. It had a single free Cys153 which 
was equivalent to the Cys107 of the mammalian core antigen. This cysteine was buried 
(5).
Further, Florian Schodel and his group carried out the expression of recombinant 
HBeAg in E.coli. They also isolated C-terminally truncated HBcAg from E.coli. They 
found that HBcAg and truncated HBcAg formed 27nm particles and displayed HBc 
antigenicity. In contrast, the recombinant HBeAg demonstrated HBe antigenicity but did 
not form uniform particles. They stated that the presence of the 10 pre-core amino acids 
prevented the formation of the particle. Therefore, the group carried out tests to analyze 
which of the amino acids were responsible for preventing the particle formation. They 
substituted cysteine to glutamine at position 7 and found that the particle forming 
capabilities were restored. Thus, they concluded that cysteine at position 7 appeared to 
be responsible for the prevention of particle assembly in the HBeAg biosynthesis 
pathway and hypothesized that the failure to assemble into uniform particles may be 
due to  additional or different disulfide bonds (6).
Moreover, Georg Wasenauer and his group demonstrated the relevance of 
cysteine residues for the biosynthesis and antigenicity of human hepatitis B ‘E protein’. 
The group made vaccinia virus  recombinants that encoded the HBe protein. They found 
that the mature form of the secretory core protein (HBe) of human hepatitis  B virus 
contained four cysteines which were located at positions -7, 48, 61 and 107. Also, there 
was a cysteine at position 183 which was  cleaved during maturation of the protein. 
Further, they also found from their studies that the cysteines at position -7 and 61 were 
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crucial for HBe biosynthesis. Moreover, the di-mer formation was due to Cys-61-Cys-61 
disulfide bridges that were formed only if the cysteine at -7 was not present. In the wild 
type, these disulfide bridges between two cysteines 61 were inhibited by an intra-
molecular disulfide bridge between the cysteine at position -7 and one of the internal 
cysteines. They further observed that the cysteine at position 61 was important for HBe 
biosynthesis because on mutating this  cysteine, the HBe proteins were formed but were 
either poorly secreted or possessed different antigenicity (7).
Michael Nassal and his  group found that an intra-molecular disulfide bridge 
between Cys-7 and Cys61 determined the structure of the secretory core gene product 
HBeAg of hepatitis  B virus which were obtained from human liver cell lines. They also 
found that Cys-7 formed an intra-molecular disulfide bond to Cys61. In the absence of 
Cys-7, secretion was relatively efficient and independent of Cys61. However, the 
molecules were exported as homodimers  exhibiting both HBe and HBc antigenicity. In 
the absence of Cys61, the non-paired Cys-7 interfered with secretion efficiency. 
Moreover, they also observed that the amino acids flanking Cys-7 also contributed to 
the formation of disulfide bonds. They concluded that the Cys-7/Cys61 bond imposed a 
conformational change that helped in the secretion of the protein and also gave the 
protein distinct biophysical and antigenic properties (8).
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Chapter 3: Hypothesis
HBcAg and HBeAg share a large portion of their amino acid sequence. 
However, HBcAg assembles into uniform particles, while HBeAg has been reported to 
be heterogeneous in size.  Because the truncated HBcAg and full length HBcAg have 
identical disulfide bonding patterns, and identical particle morphology, and because 
HBeAg differs from the truncated HBcAg only by the presence of the 10 amino acid pre-
core sequence, which contains an additional cysteine, we hypothesize that differences 
in disulfide bonding may contribute to their structural and antigenic differences. An inter-
molecular disulfide bond formed between Cys61 of identical monomers gives rise to the 
di-mers which form HBeAg. We hypothesize that either this structure cannot form or if it 
does still form in HBeAg, its further assembly into normal particulate HBeAg is 
prevented by disulfide bonds involving Cys-7 to form a chain. The following is the 
diagrammatic representation of the hypothesis.
Figure 4. Hypothetical disulfide bridging pattern in HBe
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In order to test the hypothesis, the following experiments were carried out on 
native and mutant recombinant HBeAg:
1. Expression and purification of recombinant HBeAg in E.coli.
2. Expression and purification of mutants of HBeAg with serine substitutions at 
cysteine residues.
3. Circular dichroism, Light scattering, Estimation of free sulfhydryl groups  using 
Ellman’s reagent and Effect of decreasing concentration of reducing agent on 
HBeAg and its  mutants to distinguish structural characteristics and disulfide bonding 
pattern.
13
Chapter 4: Methods and Materials
Plasmid Construction
Dr. Darrell Peterson constructed the HBeAg and the -7S plasmids. The vector 
used to construct the plasmids was pKK223-3. The following are the plasmids and their 
mutations which were synthesized using the HBeAg and -7S plasmids as template 
DNA:
1. HBeAg: Wild type
2. -7S: HBe with mutation of cysteine at position -7 to a serine
3. -7S A: HBe with mutation of cysteine at position -7 and 48 to a serine 
4. -7S B: HBe with mutation of cysteine at position -7 and 61 to a serine
5. -7S C: HBe with mutation of cysteine at position -7 and 107 to a serine
6. PCA: HBe with mutation of cysteine at position 48 to a serine
7. PCB: HBe with mutation of cysteine at position 61 to a serine
8. PCC: HBe with mutation of cysteine at position 107 to a serine
The Stratagene QuickchangeII Site-directed Mutagenesis kit was used to carry 
out the mutations. The first step was to design primers  and order their synthesis. The 
following parameters were used to design primers:
• All primers were 25 - 45 base pairs in length.
• The melting point of all the primers was not more than 78 degrees C.
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• The primers were designed in such a way that the desired mutation was in the 
middle of the primer and there were 10 - 15 base pairs flanking on each side of the 
mutation.
• Moreover, the minimum GC content was 40% and all the primers terminated 
with one or more G or C.
Once the primers were designed, they were synthesized by the VCU Nucleic 
Acids Core Facility. The primers, along with the appropriate template were then used to 
make the mutants. For mutants PCA, PCB and PCC, HBeAg plasmid was used as the 
template DNA since only the cysteine at positions 48, 61 and 107 respectively were 
supposed to be mutated. For mutants -7S A, -7S B and -7S C, the -7S plasmid was 
used as  the template DNA, since it already had the cysteine at -7 mutated and so 
further only mutations of cysteine at positions  48, 61 and 107 respectively had to be 
carried out. 
The following are the primers synthesized:
1. TTA GAG TCT CCT GAG CAT TCT TCA CCT CAC CAT ACT GCA CTC
2. GAG TGC AGT ATG GTG AGG TGA AGA ATG CTC AGG AGA CTC TAA
3. AGG CAA GCA ATT CTT TCC TGG GGG GAA CTA ATG
4. CAT TAG TTC CCC CCA GGA AAG AAT TGC TTG CCT
5. CTC TTG TGG TTT CAC ATT TCT TCT CTC ACT TTT GGA AGA G
6. C TCT TCC AAA AGT GAG AGA AGA AAT GTG AAA CCA CAA GAG
The following are the sequences of the template DNA with the primers for each 
mutant shown at the position of each mutation.
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PCA
         ttgtgagcggataacaatttcacataaggaggaaaaaaccATGGATATCGAtCCTTATAA
       1 ---------+---------+---------+---------+---------+---------+ 60
         aacactcgcctattgttaaagtgtattcctccttttttggTACCTATAGCTaGGAATATT
 
a        L  *  A  D  N  N  F  T  *  G  G  K  N  H  G  Y  R  S  L  *   -
b         C  E  R  I  T  I  S  H  K  E  E  K  T  M  D  I  D  P  Y  K  -
c          V  S  G  *  Q  F  H  I  R  R  K  K  P  W  I  S  I  L  I  K -
 
         AGAATTTGGAGCTACTGTGGAGTTACTCTCGTTTTTGCCTTCTGACTTCTTTCCTTCAGT
      61 ---------+---------+---------+---------+---------+---------+ 120
         TCTTAAACCTCGATGACACCTCAATGAGAGCAAAAACGGAAGACTGAAGAAAGGAAGTCA
 
a        R  I  W  S  Y  C  G  V  T  L  V  F  A  F  *  L  L  S  F  S   -
b         E  F  G  A  T  V  E  L  L  S  F  L  P  S  D  F  F  P  S  V  -
c          N  L  E  L  L  W  S  Y  S  R  F  C  L  L  T  S  F  L  Q  Y -
 
        BglII
            |                                       TTAGAGTCTCCTGAGCA
         ACGAGATCTTCTAGATACCGCCTCAGCTCTGTATCGGGAAGCCTTAGAGTCTCCTGAGCA
     121 ---------+---------+---------+---------+---------+---------+ 180
         TGCTCTAGAAGATCTATGGCGGAGTCGAGACATAGCCCTTCGGAATCTCAGAGGACTCGT
 
a        T  R  S  S  R  Y  R  L  S  S  V  S  G  S  L  R  V  S  *  A   -
b         R  D  L  L  D  T  A  S  A  L  Y  R  E  A  L  E  S  P  E  H  -
c          E  I  F  *  I  P  P  Q  L  C  I  G  K  P  *  S  L  L  S  I -
        
         TTCTTCACCTCACCATACTGCACTC
         TTGTTCACCTCACCATACTGCACTCAGGCAAGCAATTCTTTGCTGGGGGGAACTAATGAC
     181 ---------+---------+---------+---------+---------+---------+ 240
         AACAAGTGGAGTGGTATGACGTGAGTCCGTTCGTTAAGAAACGACCCCCCTTGATTACTG
 
a        L  F  T  S  P  Y  C  T  Q  A  S  N  S  L  L  G  G  T  N  D   -
b         C  S  P  H  H  T  A  L  R  Q  A  I  L  C  W  G  E  L  M  T  -
c          V  H  L  T  I  L  H  S  G  K  Q  F  F  A  G  G  N  *  *  L -
   
         TCTAGCTACCTGGGTGGGTGTTAATTTGGAAGATCCAGCGTCTAGAGACCTAGTAGTCAG
     241 ---------+---------+---------+---------+---------+---------+ 300
         AGATCGATGGACCCACCCACAATTAAACCTTCTAGGTCGCAGATCTCTGGATCATCAGTC
 
a        S  S  Y  L  G  G  C  *  F  G  R  S  S  V  *  R  P  S  S  Q   -
b         L  A  T  W  V  G   V  N  L  E  D  P  A  S  R  D  L  V  V  S  -
c          *  L  P  G  W  V  L  I  W  K  I  Q  R  L  E  T  *  *  S  V -
 
         TTATGTCAACACTAATATGGGCCTAAAGTTCAGGCAACTCTTGTGGTTTCACATTTCTTG
     301 ---------+---------+---------+---------+---------+---------+ 360
         AATACAGTTGTGATTATACCCGGATTTCAAGTCCGTTGAGAACACCAAAGTGTAAAGAAC
 
a        L  C  Q  H  *  Y  G  P  K  V  Q  A  T  L  V  V  S  H  F  L   -
b         Y  V  N  T  N  M  G  L  K  F  R  Q  L  L  W  F  H  I  S  C  -
c          M  S  T  L  I  W  A  *  S  S  G  N  S  C  G  F  T  F  L  V -
 
         TCTCACTTTTGGAAGAGAAACAGTTATAGAGTATTTGGTGTCTTTCGGAGTGTGGATTCG
     361 ---------+---------+---------+---------+---------+---------+ 420
         AGAGTGAAAACCTTCTCTTTGTCAATATCTCATAAACCACAGAAAGCCTCACACCTAAGC
 
a        S  H  F  W  K  R  N  S  Y  R  V  F  G  V  F  R  S  V  D  S   -
16
b         L  T  F  G  R  E  T  V  I  E  Y  L  V  S  F  G  V  W  I  R  -
c          S  L  L  E  E  K  Q  L  *  S  I  W  C  L  S  E  C  G  F  A -
 
         CACTCCTCCAGCTTATAGACCACCAAATGCCCCTATCCTATCAACACTTCCGGAGACTAC
     421 ---------+---------+---------+---------+---------+---------+ 480
         GTGAGGAGGTCGAATATCTGGTGGTTTACGGGGATAGGATAGTTGTGAAGGCCTCTGATG
 
a        H  S  S  S  L  *  T  T  K  C  P  Y  P  I  N  T  S  G  D  Y   -
b         T  P  P  A  Y  R  P  P  N  A  P  I  L  S  T  L  P  E  T  T  -
c          L  L  Q  L  I  D  H  Q  M  P  L  S  Y  Q  H  F  R  R  L  L -
 
         TGTTGTTAGACGACGAGGCAGGTCCCCTAGAAGAAGAACTCCCTCGCCTCGCAGACGAAG
     481 ---------+---------+---------+---------+---------+---------+ 540
         ACAACAATCTGCTGCTCCGTCCAGGGGATCTTCTTCTTGAGGGAGCGGAGCGTCTGCTTC
 
a        C  C  *  T  T  R  Q  V  P  *  K  K  N  S  L  A  S  Q  T  K   -
b         V  V  R  R  R  G  R  S  P  R  R  R  T  P  S  P  R  R  R  R  -
c          L  L  D  D  E  A  G  P  L  E  E  E  L  P  R  L  A  D  E  G -
 
                           BglII
                               |
         GTCTCAATCGCCGCGTCGCAGAAGATCTCAATCTCGGGAATCTCAATGTTAGTATTCCTT
     541 ---------+---------+---------+---------+---------+---------+ 600
         CAGAGTTAGCGGCGCAGCGTCTTCTAGAGTTAGAGCCCTTAGAGTTACAATCATAAGGAA
 
a        V  S  I  A  A  S  Q  K  I  S  I  S  G  I  S  M  L  V  F  L   -
b         S  Q  S  P  R  R  R  R  S  Q  S  R  E  S  Q  C  *  Y  S  L  -
c          L  N  R  R  V  A  E  D  L  N  L  G  N  L  N  V  S  I  P  W -
Forward Primer: TTA GAG TCT CCT GAG CAT TCT TCA CCT CAC CAT ACT GCA CTC
Reverse Primer: GAG TGC AGT ATG GTG AGG TGA AGA ATG CTC AGG AGA CTC TAA
Length:            42
GC Content:   47.6 %
Melting Temp.: 66.1 ºC
17
PCB
         ttgtgagcggataacaatttcacataaggaggaaaaaaccATGGATATCGAtCCTTATAA
       1 ---------+---------+---------+---------+---------+---------+ 60
         aacactcgcctattgttaaagtgtattcctccttttttggTACCTATAGCTaGGAATATT
 
a        L  *  A  D  N  N  F  T  *  G  G  K  N  H  G  Y  R  S  L  *   -
b         C  E  R  I  T  I  S  H  K  E  E  K  T  M  D  I  D  P  Y  K  -
c          V  S  G  *  Q  F  H  I  R  R  K  K  P  W  I  S  I  L  I  K -
 
         AGAATTTGGAGCTACTGTGGAGTTACTCTCGTTTTTGCCTTCTGACTTCTTTCCTTCAGT
      61 ---------+---------+---------+---------+---------+---------+ 120
         TCTTAAACCTCGATGACACCTCAATGAGAGCAAAAACGGAAGACTGAAGAAAGGAAGTCA
 
a        R  I  W  S  Y  C  G  V  T  L  V  F  A  F  *  L  L  S  F  S   -
b         E  F  G  A  T  V  E  L  L  S  F  L  P  S  D  F  F  P  S  V  -
c          N  L  E  L  L  W  S  Y  S  R  F  C  L  L  T  S  F  L  Q  Y -
 
        BglII
            |
         ACGAGATCTTCTAGATACCGCCTCAGCTCTGTATCGGGAAGCCTTAGAGTCTCCTGAGCA
     121 ---------+---------+---------+---------+---------+---------+ 180
         TGCTCTAGAAGATCTATGGCGGAGTCGAGACATAGCCCTTCGGAATCTCAGAGGACTCGT
 
a        T  R  S  S  R  Y  R  L  S  S  V  S  G  S  L  R  V  S  *  A   -
b         R  D  L  L  D  T  A  S  A  L  Y  R  E  A  L  E  S  P  E  H  -
c          E  I  F  *  I  P  P  Q  L  C  I  G  K  P  *  S  L  L  S  I -
 
                                 
                                  AGGCAAGCAATTCTTTCCTGGGGGGAACTAATG
         TTGTTCACCTCACCATACTGCACTCAGGCAAGCAATTCTTTGCTGGGGGGAACTAATGAC
     181 ---------+---------+---------+---------+---------+---------+ 240
         AACAAGTGGAGTGGTATGACGTGAGTCCGTTCGTTAAGAAACGACCCCCCTTGATTACTG
 
a        L  F  T  S  P  Y  C  T  Q  A  S  N  S  L  L  G  G  T  N  D   -
b         C  S  P  H  H  T  A  L  R  Q  A  I  L  C  W  G  E  L  M  T  -
c          V  H  L  T  I  L  H  S  G  K  Q  F  F  A  G  G  N  *  *  L -
 
         TCTAGCTACCTGGGTGGGTGTTAATTTGGAAGATCCAGCGTCTAGAGACCTAGTAGTCAG
     241 ---------+---------+---------+---------+---------+---------+ 300
         AGATCGATGGACCCACCCACAATTAAACCTTCTAGGTCGCAGATCTCTGGATCATCAGTC
 
a        S  S  Y  L  G  G  C  *  F  G  R  S  S  V  *  R  P  S  S  Q   -
b         L  A  T  W  V  G  V  N  L  E  D  P  A  S  R  D  L  V  V  S  -
c          *  L  P  G  W  V  L  I  W  K  I  Q  R  L  E  T  *  *  S  V -
 
         TTATGTCAACACTAATATGGGCCTAAAGTTCAGGCAACTCTTGTGGTTTCACATTTCTTG
     301 ---------+---------+---------+---------+---------+---------+ 360
         AATACAGTTGTGATTATACCCGGATTTCAAGTCCGTTGAGAACACCAAAGTGTAAAGAAC
 
a        L  C  Q  H  *  Y  G  P  K  V  Q  A  T  L  V  V  S  H  F  L   -
b         Y  V  N  T  N  M  G  L  K  F  R  Q  L  L  W  F  H  I  S  C  -
c          M  S  T  L  I  W  A  *  S  S  G  N  S  C  G  F  T  F  L  V -
 
         TCTCACTTTTGGAAGAGAAACAGTTATAGAGTATTTGGTGTCTTTCGGAGTGTGGATTCG
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     361 ---------+---------+---------+---------+---------+---------+ 420
         AGAGTGAAAACCTTCTCTTTGTCAATATCTCATAAACCACAGAAAGCCTCACACCTAAGC
 
a        S  H  F  W  K  R  N  S  Y  R  V  F  G  V  F  R  S  V  D  S   -
b         L  T  F  G  R  E  T  V  I  E  Y  L  V  S  F  G  V  W  I  R  -
c          S  L  L  E  E  K  Q  L  *  S  I  W  C  L  S  E  C  G  F  A -
 
         CACTCCTCCAGCTTATAGACCACCAAATGCCCCTATCCTATCAACACTTCCGGAGACTAC
     421 ---------+---------+---------+---------+---------+---------+ 480
         GTGAGGAGGTCGAATATCTGGTGGTTTACGGGGATAGGATAGTTGTGAAGGCCTCTGATG
 
a        H  S  S  S  L  *  T  T  K  C  P  Y  P  I  N  T  S  G  D  Y   -
b         T  P  P  A  Y  R  P  P  N  A  P  I  L  S  T  L  P  E  T  T  -
c          L  L  Q  L  I  D  H  Q  M  P  L  S  Y  Q  H  F  R  R  L  L -
 
         TGTTGTTAGACGACGAGGCAGGTCCCCTAGAAGAAGAACTCCCTCGCCTCGCAGACGAAG
     481 ---------+---------+---------+---------+---------+---------+ 540
         ACAACAATCTGCTGCTCCGTCCAGGGGATCTTCTTCTTGAGGGAGCGGAGCGTCTGCTTC
 
a        C  C  *  T  T  R  Q  V  P  *  K  K  N  S  L  A  S  Q  T  K   -
b         V  V  R  R  R  G  R  S  P  R  R  R  T  P  S  P  R  R  R  R  -
c          L  L  D  D  E  A  G  P  L  E  E  E  L  P  R  L  A  D  E  G -
 
                           BglII
                               |
         GTCTCAATCGCCGCGTCGCAGAAGATCTCAATCTCGGGAATCTCAATGTTAGTATTCCTT
     541 ---------+---------+---------+---------+---------+---------+ 600
         CAGAGTTAGCGGCGCAGCGTCTTCTAGAGTTAGAGCCCTTAGAGTTACAATCATAAGGAA
 
a        V  S  I  A  A  S  Q  K  I  S  I  S  G  I  S  M  L  V  F  L   -
b         S  Q  S  P  R  R  R  R  S  Q  S  R  E  S  Q  C  *  Y  S  L  -
c          L  N  R  R  V  A  E  D  L  N  L  G  N  L  N  V  S  I  P  W -
Forward Primer:  AGG CAA GCA ATT CTT TCC TGG GGG GAA CTA ATG
Reverse Primer:  CAT TAG TTC CCC CCA GGA AAG AAT TGC TTG CCT
Length:            33
GC Content:  48.5 %
Melting Temp.: 65.0 ºC
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PCC
         ttgtgagcggataacaatttcacataaggaggaaaaaaccATGGATATCGAtCCTTATAA
       1 ---------+---------+---------+---------+---------+---------+ 60
         aacactcgcctattgttaaagtgtattcctccttttttggTACCTATAGCTaGGAATATT
 
a        L  *  A  D  N  N  F  T  *  G  G  K  N  H  G  Y  R  S  L  *   -
b         C  E  R  I  T  I  S  H  K  E  E  K  T  M  D  I  D  P  Y  K  -
c          V  S  G  *  Q  F  H  I  R  R  K  K  P  W  I  S  I  L  I  K -
 
         AGAATTTGGAGCTACTGTGGAGTTACTCTCGTTTTTGCCTTCTGACTTCTTTCCTTCAGT
      61 ---------+---------+---------+---------+---------+---------+ 120
         TCTTAAACCTCGATGACACCTCAATGAGAGCAAAAACGGAAGACTGAAGAAAGGAAGTCA
 
a        R  I  W  S  Y  C  G  V  T  L  V  F  A  F  *  L  L  S  F  S   -
b         E  F  G  A  T  V  E  L  L  S  F  L  P  S  D  F  F  P  S  V  -
c          N  L  E  L  L  W  S  Y  S  R  F  C  L  L  T  S  F  L  Q  Y -
 
        BglII
            |
         ACGAGATCTTCTAGATACCGCCTCAGCTCTGTATCGGGAAGCCTTAGAGTCTCCTGAGCA
     121 ---------+---------+---------+---------+---------+---------+ 180
         TGCTCTAGAAGATCTATGGCGGAGTCGAGACATAGCCCTTCGGAATCTCAGAGGACTCGT
 
a        T  R  S  S  R  Y  R  L  S  S  V  S  G  S  L  R  V  S  *  A   -
b         R  D  L  L  D  T  A  S  A  L  Y  R  E  A  L  E  S  P  E  H  -
c          E  I  F  *  I  P  P  Q  L  C  I  G  K  P  *  S  L  L  S  I -
 
         TTGTTCACCTCACCATACTGCACTCAGGCAAGCAATTCTTTGCTGGGGGGAACTAATGAC
     181 ---------+---------+---------+---------+---------+---------+ 240
         AACAAGTGGAGTGGTATGACGTGAGTCCGTTCGTTAAGAAACGACCCCCCTTGATTACTG
 
a        L  F  T  S  P  Y  C  T  Q  A  S  N  S  L  L  G  G  T  N  D   -
b         C  S  P  H  H  T  A  L  R  Q  A  I  L  C  W  G  E  L  M  T  -
c          V  H  L  T  I  L  H  S  G  K  Q  F  F  A  G  G  N  *  *  L -
 
         TCTAGCTACCTGGGTGGGTGTTAATTTGGAAGATCCAGCGTCTAGAGACCTAGTAGTCAG
     241 ---------+---------+---------+---------+---------+---------+ 300
         AGATCGATGGACCCACCCACAATTAAACCTTCTAGGTCGCAGATCTCTGGATCATCAGTC
 
a        S  S  Y  L  G  G  C  *  F  G  R  S  S  V  *  R  P  S  S  Q   -
b         L  A  T  W  V  G  V  N  L  E  D  P  A  S  R  D  L  V  V  S  -
c          *  L  P  G  W  V  L  I  W  K  I  Q  R  L  E  T  *  *  S  V -
 
                                              CTCTTGTGGTTTCACATTTCTTC
         TTATGTCAACACTAATATGGGCCTAAAGTTCAGGCAACTCTTGTGGTTTCACATTTCTTG
     301 ---------+---------+---------+---------+---------+---------+ 360
         AATACAGTTGTGATTATACCCGGATTTCAAGTCCGTTGAGAACACCAAAGTGTAAAGAAC
 
a        L  C  Q  H  *  Y  G  P  K  V  Q  A  T  L  V  V  S  H  F  L   -
b         Y  V  N  T  N  M  G  L  K  F  R  Q  L  L  W  F  H  I  S  C  -
c          M  S  T  L  I  W  A  *  S  S  G  N  S  C  G  F  T  F  L  V -
 
         TCTCACTTTTGGAAGAG   
         TCTCACTTTTGGAAGAGAAACAGTTATAGAGTATTTGGTGTCTTTCGGAGTGTGGATTCG
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     361 ---------+---------+---------+---------+---------+---------+ 420
         AGAGTGAAAACCTTCTCTTTGTCAATATCTCATAAACCACAGAAAGCCTCACACCTAAGC
 
a        S  H  F  W  K  R  N  S  Y  R  V  F  G  V  F  R  S  V  D  S   -
b         L  T  F  G  R  E  T  V  I  E  Y  L  V  S  F  G  V  W  I  R  -
c          S  L  L  E  E  K  Q  L  *  S  I  W  C  L  S  E  C  G  F  A -
 
         CACTCCTCCAGCTTATAGACCACCAAATGCCCCTATCCTATCAACACTTCCGGAGACTAC
     421 ---------+---------+---------+---------+---------+---------+ 480
         GTGAGGAGGTCGAATATCTGGTGGTTTACGGGGATAGGATAGTTGTGAAGGCCTCTGATG
 
a        H  S  S  S  L  *  T  T  K  C  P  Y  P  I  N  T  S  G  D  Y   -
b         T  P  P  A  Y  R  P  P  N  A  P  I  L  S  T  L  P  E  T  T  -
c          L  L  Q  L  I  D  H  Q  M  P  L  S  Y  Q  H  F  R  R  L  L -
 
         TGTTGTTAGACGACGAGGCAGGTCCCCTAGAAGAAGAACTCCCTCGCCTCGCAGACGAAG
     481 ---------+---------+---------+---------+---------+---------+ 540
         ACAACAATCTGCTGCTCCGTCCAGGGGATCTTCTTCTTGAGGGAGCGGAGCGTCTGCTTC
 
a        C  C  *  T  T  R  Q  V  P  *  K  K  N  S  L  A  S  Q  T  K   -
b         V  V  R  R  R  G  R  S  P  R  R  R  T  P  S  P  R  R  R  R  -
c          L  L  D  D  E  A  G  P  L  E  E  E  L  P  R  L  A  D  E  G -
 
                           BglII
                               |
         GTCTCAATCGCCGCGTCGCAGAAGATCTCAATCTCGGGAATCTCAATGTTAGTATTCCTT
     541 ---------+---------+---------+---------+---------+---------+ 600
         CAGAGTTAGCGGCGCAGCGTCTTCTAGAGTTAGAGCCCTTAGAGTTACAATCATAAGGAA
 
a        V  S  I  A  A  S  Q  K  I  S  I  S  G  I  S  M  L  V  F  L   -
b         S  Q  S  P  R  R  R  R  S  Q  S  R  E  S  Q  C  *  Y  S  L  -
c          L  N  R  R  V  A  E  D  L  N  L  G  N  L  N  V  S  I  P  W -
Forward Primer: CTC TTG TGG TTT CAC ATT TCT TCT CTC ACT TTT GGA AGA G
Reverse Primer: C TCT TCC AAA AGT GAG AGA AGA AAT GTG AAA CCA CAA GAG
Length:            40
GC Content:  40.0 %
Melting Temp.: 62.2 ºC
The same above mentioned forward and reverse primers were used for synthesis 
of mutants -7S A, -7S B and -7S C since the same point mutations  were to be carried 
out except that these mutants also had the cysteine at position -7 mutated. In these 
cases, the DNA template used was the -7S plasmid since this mutant already had  the 
cysteine at -7 mutated.
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Mutations were carried out by PCR, according to the directions supplied in the 
Quick Change kit. The reaction mixtures for the PCR reactions contained: 5µl of 10X 
reaction buffer, 3µl of template plasmid, 1µl of the appropriate mutagenic primer, 1µl of 
dNTP mix, and  39µl of water to give a final volume of  50µl.
To all of the above reaction mixtures, 1µl of pfuDNA polymerase was added. The 
reaction mixtures were then put in a PCR machine and the following program was set:
Segment Cycles Temperature Time
1 1 95℃ 30 seconds
2 16 95℃ 30 seconds
55℃ 1 minute
68℃ 5 minutes
Table 1. PCR Cycles
After the PCR reaction was carried out, the tubes were kept on ice for 2 minutes 
so that the reaction was cooled.
The PCR products were then subjected to digestion with Dpn I restriction enzyme 
in order to digest the non-mutated, methylated parental DNA strand. To do this, 1 µl of 
Dpn I restriction enzyme was added to each of the PCR products. The PCR products 
were mixed and then incubated at 37 ℃ for 1 hour.
These Dpn I treated PCR products were transformed in XL1-Blue 
Supercompetent cells. The XL1-Blue cells were thawed and 50µl of cells  were taken to 
transform each PCR product. To this 1µl of Dpn I treated PCR product was added. This 
mixture was mixed and was incubated on ice for 30 minutes. The mixture was then heat 
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pulsed at 42℃ for 45 seconds. Then the mixture was immediately put on ice for 2 
minutes. To this mixture, 500µl of LB was added and it was incubated at 37℃ for 1 hour.
This  mixture was then plated on ampicillin plates and incubated for 37℃ for more 
than 16 hours. After 16 hours, the plates had colonies. Colonies from each plate were 
picked and inoculated in 10ml of LB containing 10µl of ampicillin (50µg/ml) and 
incubated at 37℃ in a shaker overnight.
Plasmid purification was then carried out on all the 10ml cultures by using the 
Qiagen QIAprep Spin protocol, exactly according to the directions supplied by the 
company.
Thus, the plasmids of all the mutants were obtained this way and they were sent 
for sequencing at the DNA sequencing core facility. The following are the sequences of 
the proteins that would be synthesized form each plasmids as determined by translation 
of the sequence obtained. In the following sequences the mutations are marked in red.
-7S A
Reading Frame 2 – Forward Primer
VRDLLDTASALYREALESPEHSSPHHTALRQAILCWGELMTLATWVGVNLEDP
ASRDLVVSYVNTNMGLKFRQLLWFHISCLTFGRETVIEYLVSFGVWIRTPPAYRPPNAP
IL
Reading Frame 3 -  Reverse Primer
MSKLSLGWLWGMDIDPYKEFGATVELLSFLPSDFFPSVRDLLDTASALYREAL
ESPEHSSPHHTALRQAILCWGELMTLATWVGVNLEDPASRDLVVSYVNTNMGLKFR
QLLWFHISCLTFGRETVIEYLVSFGV
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-7S B
Reading Frame 1 – Forward Primer
VRDLLDTASALYREALESPEHCSPHHTALRQAILSWGELMTLATWVGVNLEDP
ASRDLVVSYVNTNMGLKFRQLLWFHISCLTFGRETVIEYLVSFGVWIRTPPAYRPPNAP
ILSTLPETTVV
Reading Frame  3 – Reverse Primer
MSKLSLGWLWGMDIDPYKEFGATVELLSFLPSDFFPSVRDLLDTASALYREAL
ESPEHCSPHHTALRQAILSWGELMTLATWVGVNLEDPASRDLVVSYVNTNMGLKFR
QLLWFHISCLTFGRETVIEYLVSFGV
-7S C
Reading Frame 1 - Reverse Primer
MSKLSLGWLWGMDIDPYKEFGATVELLSFLPSDFFPSVRDLLDTASALYREAL
ESPEHCSPHHTALRQAILCWGELMTLATWVGVNLEDPASRDLVVSYVNTNMGLKFR
QLLWFHISSLTFGRETVIEYLVSFGV
PCA
Reading frame 2 - Reverse Primer
MSKLCLGWLWGMDIDPYKEFGATVELLSFLPSDFFPSVRDLLDTASALYREAL
ESPEHSSPHHTALRQAILCWGELMTLATWVGVNLEDPASRDLVVSYVNTNMGLKFR
QLLWFHISCLTFGRETVIEYLVSFGV
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PCB
Reading Frame 2 - Reverse Primer
MSKLCLGWLWGMDIDPYKEFGATVELLSFLPSDFFPSVRDLLDTASALYREAL
ESPEHCSPHHTALRQAILSWGELMTLATWVGVNLEDPASRDLVVSYVNTNMGLKFR
QLLWFHISCLTFGRETVIEYLVSFGV
PCC
Reading Frame 1 - Reverse Primer
MSKLCLGWLWGMDIDPYKEFGATVELLSFLPSDFFPSVRDLLDTASALYREAL
ESPEHCSPHHTALRQAILCWGELMTLATWVGVNLEDPASRDLVVSYVNTNMGLKFR
QLLWFHISSLTFGRETVIEYLVSFGV
Expression and Purification
The plasmids for all the mutants were freshly transformed into E.coli every time 
before expression. This was because it was observed that after repeated passage, the 
bacteria exhibited a large decrease in the level of protein expression. Further, it was 
also observed that when some of the mutants when transformed in different strains of 
E.coli competent cells (top10 or TB1), the level of protein expression was higher as 
measured by  higher antigenic activity.  Therefore, the HBeAg, PCA, PCB, PCC and -7S 
C plasmids were transformed into E.coli TB1 competent cells  whereas, -7S, -7S A and 
-7S B plasmids were transformed into E.coli Top 10 competent cells. 
The transformation was carried out via electroporation. For this 2mm 
electroporation cuvettes were used. 50µl of electro-competent TB1/Top 10 cells were 
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taken and 1.5µl of plasmid was added to it. This  was mixed well and it was allowed to sit 
on ice for 15 minutes. The mixture was then transferred to the 2mm electroporation 
cuvette and put in the electroporator. The mixture was pulsed and immediately taken 
out from the electroporation cuvette, 1ml of LB was added to it. This was then incubated 
on a shaker at 37℃ for 1 hour. After an hour, 20µl from it was plated on ampicillin plates 
and these plates were incubated at 37℃ for 16 hours.
A colony was picked up from the plate and inoculated in 10ml of LB containing 
10µl of ampicillin (from ampicillin stock - 50mg/ml). This  was allowed to grow on a 
shaker at 37℃ overnight. TYN media was prepared and autoclaved. The following is the 
recipe for TYN media:
• 100g NZamine
• 100g Yeast Extract
• 50g Sodium Chloride
• Made up to 10 liter with deionized water 
• pH was adjusted to 7.5
1 liter of the above was placed in 2 liter flasks and autoclaved. Also, 20% glucose 
solution (0.2 grams/ml in water) was prepared and autoclaved separately. When cooled, 
the final TYN medium was prepared by adding 5 ml of the 20 % glucose solution and 1 
ml of ampicillin (50 mg/ml) to each liter. 2-3 ml of overnight culture was used to 
inoculate each flask.
This  cultures were incubated at 37℃ on a shaker for 24 hours. The cells were 
then centrifuged at 5000rpm for 15 minutes and the bacterial pellets were collected. 
These pellets were resuspended in 20mM Tris buffer pH 8. The cells were lysed by 
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passing them through a high pressure homogenizer (Avestin Emulsiflex) at 20,000 psi 
pressure. The lysate was then centrifuged at 15000 rpm for 30 minutes and the 
supernatant was collected. The supernatant was then subjected to Ammonium sulfate 
(20% saturation) precipitation. It was allowed to stand at 4℃ for an hour and then 
centrifuged at 15000rpm for 30 minutes. The pellets were collected and re-dissolved in 
a minimum volume of 20mM Tris buffer pH 8.0. These re-dissolved pellets were then 
fractionated by chromatography on a Cross-linked Sepharose CL4B column. The 
fractions were collected and the protein elution profile was determined by monitoring the 
absorbance at 280 nm. Fractions were analyzed by SDS PAGE to determine the 
location of the desired protein. The fractions containing the protein were pooled. This 
pooled protein was then concentrated in a centrifugal concentrator with a cut-off of 
100,000 molecular weight. All of the proteins were purified according to this procedure.
All the proteins were run on SDS-PAGE gels along with a molecular marker. 
Further, ELISA was also carried out to check the antigenic activity of the proteins 
obtained.
ELISA
For carrying out an ELISA, IgG was first purified from the serum of a rabbit that 
had been immunized with truncated HBcAg using DEAE Affi-gel Blue (Bio-Rad, Inc). 
This  was done using DEAE Affi-gel Blue (Bio-Rad, Inc), according to the manufacturers 
instructions. Once the pure IgG was obtained, it was used to coat plates. The purified 
IgG was diluted to a concentration of 20µg/ml, in 1X coating buffer (10 mM sodium 
bicarbonate/10 mM sodium carbonate buffer). 50µl of this was pipetted in each well and 
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it was allowed to stand at room temperature for 2 hours. Peroxidase conjugated IgG 
was also prepared. Periodate-activated horseradish peroxidase was prepared and 
stored in 1 mg aliquots at -80 degrees until use (24). Aliquots  of the purified IgG were 
freeze dried from 1mM bicarbonate buffer. It, too, was stored in 1mg aliquots. One vial 
of IgG and one vial of activated peroxidase were thawed and mixed. The IgG dissolved 
immediately. A solution of 1M sodium cyanoborohydride (MW = 62, therefore 62mg/ml) 
in 10X coating buffer (10 mM sodium carbonate/10 mM sodium bicarbonate) was then 
prepared. 20µl of the 1M sodium cyanoborohydride solution was added to the 
peroxidase/IgG solution and it was allowed to stand for 2 hours at room temperature 
after which it was ready to be used. It was then stored in a refrigerator.
For each assay, one strip was taken out from the previously coated IgG plates 
and washed with water. 100µl of BSA (1gram Bovine Serum Albumin in 50ml of 50mM 
Tris  buffer pH 8.0) was added to all the wells. 10µl of the sample was added to the last 
well and this was then serially diluted by transferring 10µl to four other wells. This gave 
a dilutions of 1:10 – 1:10000. The top two wells were left as negative controls. The strips 
were allowed to stand for 1 hour after which, they were washed with water. To these 
wells, 50µl of peroxidase-conjugated IgG (2µl of peroxidase labelled IgG in 1ml of BSA) 
was added. This was allowed to stand for 30 minutes. These strips were then washed 
extensively with water and 50µl of substrate (BioRad TMBlue or Abbott Laboratories 
OPD) was added. 
The color was allowed to develop for 10 minutes and the reaction was then 
stopped by adding 100µl of 1M sulphuric acid to each well. The plate was then read at 
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450 nm (TMBlue) or 490 nm (OPD). All the readings were then made on a Bio-Tek plate 
reader.
Reduction or Reduction and Alkylation of HBeAg
Reduction of HBeAg disulfide bonds
The effects of varying the concentration of reducing agent on HBeAg as well as 
each of the mutants  was examined by SDS PAGE. To carry out this experiment, 40µl of 
SDS sample buffer containing no reducing agent was placed in a micro-centrifuge tube. 
13 micro-centrifuge tubes were then taken and 20µl of SDS sample buffer containing no 
reducing agent was added to these tubes. Then, to the first tube containing 40µl of SDS 
sample buffer, 2µl of β-mercaptoethanol (14.2 M) was added and mixed properly. 20µl 
was pipetted out from this tube and added to the other tube containing 20µl of SDS 
sample buffer and this  was mixed properly. The serial dilution was  continued to the 13th 
micro-centrifuge tube giving final concentrations of mercaptoethanol of 710 mM to 0.16 
mM. 30µl of protein was then added to all the micro-centrifuge tubes and these were 
boiled and run on an SDS PAGE gel. The samples were then analyzed by SDS 
polyacrylamide gel electrophoresis.  
Reduction and Alkylation of HBeAg disulfide bonds
In order to prevent possible disulfide interchange or reformation during sample 
preparation, the above procedure was repeated. However following reduction, 
Iodoacetamide was added (100 mM) to convert all sulfhydryl groups to the carboxamido 
derivatives.  
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Quantitation of Sulfhydryl Groups
Ellman’s reagent (5,5’-dithiobis-(2-nitrobenzoic acid) was used to quantitate free 
sulfhydryl groups in the recombinant proteins. The reaction was performed as described 
in the book ‘Current Protocols in Molecular Biology’ by Frederick M. with some 
modifications. A series of standards were prepared having concentrations ranging from 
10 to 100µM cysteine. The total volume of all the tubes was then made up to 500µl with 
20mM Tris buffer pH 8.0. 50µl of Ellman’s reagent (4.0mg/ml in ethyl alcohol) was 
added and the tubes were  allowed to stand at room temperature for 15 minutes. 
Absorbance was then read at a wavelength of 412nm. The values obtained were used 
to plot a cysteine standard curve. Thereafter, for determination of the cysteine content of 
the different proteins, samples of each protein were adjusted to 40µM concentration. 
Two tubes containing 500µl of each protein were taken. One tube was treated with 0.1% 
SDS whereas the other tube was untreated. 50µl of the Ellman’s reagent was added to 
these tubes and the tubes were allowed to stand for 15 minutes at room temperature. 
Then the absorbance at 412 nm was measured. The cysteine content for the proteins 
was extrapolated from the extinction coefficient calculated from the standard curve.
An attempt was also made to reduce the HBeAg using the ReduceIM column 
from Pierce Chemical Co. This was used to establish whether the disulfide bonds were 
buried or were surface accessible for reduction. The exact procedure was followed from 
the manual provided by the company.
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Circular Dichroism
Circular dichroism was used to examine the secondary structures of all the 
proteins. The proteins were diluted to concentrations between 0.2 - 0.4mg/ml. The CD 
spectra were then obtained using a Olis CD spectrophotometer.
Light Scattering
Dynamic light scattering was used to analyze the size distribution of the particles 
(in nanometers) in a solution for each of the proteins. These studies were performed 
with a Dynapro Dynamic Light Scattering instrument (Protein Solutions, Inc). 
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Chapter 5: Results & Discussion
Expression and Purification
The wild-type recombinant HBeAg plasmid was electroporated into TB1 electro-
competent cells. A colony was picked up and grown overnight in 10ml LB containing 
ampicillin. This culture was then used to inoculate 3 liters of TYN media. After 24 hours 
incubation the cells were spun down and the pellets were resuspended in 20mM Tris 
buffer. This re-suspended pellet was then lysed in a high pressure homogenizer and the 
lysate thus obtained was centrifuged. The supernatant was collected and it was 
subjected to 20% Ammonium sulfate saturation. It was allowed to stand for an hour at 
4℃. This was then centrifuged and the pellet and supernatant were collected.
The following is  the gel which shows the steps of the purification process. The 
lysate was loaded along with the the 20% ammonium sulfate pellet and supernatant.
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                   M     S         Lys                  S      AS Pellet                  AS SN!
Figure 5. SDS PAGE gel picture of wild-type recombinant HBeAg. ‘M’ stands  for 
Molecular Marker, ‘S’ stands for wild-type recombinant HBeAg, ‘Lys’ stands for Lysate, 
‘AS Pellet’ stands for 20% ammonium sulfate pellet and ‘AS SN’ stands for 20% 
ammonium sulfate supernatant.
Based on the above gel, it is clear that the protein of interest was present in the 
20% ammonium sulfate precipitate and this  was taken for further purification by gel 
filtration chromatography.
The 20% ammonium sulfate pellet was re-suspended in 20mM Tris buffer and 
was loaded on the Sepharose CL4B column. Fractions  were collected and the protein 
elution monitored at 280 nm. The absorbance values  obtained for the fractions were 
plotted on a graph. The following profile was obtained for the wild-type recombinant 
HBeAg protein. Very similar elution profiles were obtained for all of the proteins. 
However, the magnitude of the antigen containing peak (as described below) varied.
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Figure 6. Elution profile for the wild-type recombinant HBeAg protein from 
Sepharose CL4B. The first huge peak contains  the 280nm measuring material eluted 
along with the void volume followed by the second peak which contains the wild-type 
recombinant HBeAg. 
All of the elution profiles had a very similar appearance. A large peak of 280 nm 
absorbing material eluted at the void volume of the column. Although this  peak had high 
absorbance at 280 nm, it contained little protein that was observable on SDS gels, and 
thus must represent non-protein components. It was also quite turbid, and much of the 
absorbance was actually just light scatter. It was  in the subsequent fractions that the 
antigen protein was found, as  indicated in the figure above. All the mutants eluted at the 
same positions. The fractions were run on an SDS PAGE gel to determine which of the 
fractions contained the wild-type recombinant HBeAg or other antigen protein and to 
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allow fractions of greatest purity to be pooled. The following is  gel picture showing the 
proteins present in selected fractions.
                        S     7     9     10   11    12    14    16     17    18    20    21 
!
Figure 7. SDS PAGE Gel of fractions obtained from the chromatography of wild-
type recombinant HBeAg on Sepharose CL4B. Selected fractions from the 
chromatography were run on the gel. 
Fraction 9, 10, 11 and 12 were pooled. The fractions were almost pure. These 
were then concentrated in a concentrator with a molecular weight cut-off of 100,000.  An 
SDS PAGE gel was run of the top solution and the bottom solution from the 
concentrator. All of the protein was retained by the concentrator. This was the expected 
result, since Sepharose CL4B has a molecular weight exclusion limit of about 10 million, 
the antigen elutes relatively early during the chromatography, it was expected to have 
an apparent molecular weight of many thousands. It should be noted that all of the 
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peaks eluting from the Sepharose CL4B column were examined by SDS PAGE, and no 
additional peaks containing the antigen protein were observed.
The following is  the SDS PAGE gel on which the solution retained in the 
concentrator was run along with the solution at the bottom of the concentrator.
                 M    S        Top Solution                 S       Bottom Solution 
!
Figure 8. SDS PAGE Gel picture of concentrated wild-type recombinant HBeAg. 
The ‘M’ stand for the molecular Marker, the ‘S’ stands for the wild-type recombinant 
HBeAg, the ‘Top solution’ is the solution which retained on the concentrator and the 
‘Bottom solution’ is the solution passed through the ultra filter. The top as well as bottom 
solutions were loaded in increasing concentrations in different wells.
The concentrated protein was recovered from the filter and was stored in 1ml 
aliquots at -80℃. This purification process was followed for all the mutant proteins. 
Therefore, only the SDS PAGE gel pictures are presented below.
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The -7S plasmid was  electroporated in to top10 electro-competent cells.  A three 
liter culture was grown and the protein was purified.  The gels below shows the various 
stages of purification.
                 M    S       Lys                 SN                S      AS Pellet           AS SN
!
Figure 9. SDS PAGE Gel picture of -7S. ‘M’ stands for Molecular Marker, ‘S’ stands for 
wild-type recombinant HBeAg, ‘Lys’ stands for Lysate, ‘SN’ stands for supernatant, ‘AS 
Pellet’ stands for 20% ammonium sulfate pellet and ‘AS SN’ stands for 20% ammonium 
sulfate supernatant.
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                S      7     9    10    11   12    14    16    17   18    20   21    22    23  24
!Figure 10. SDS PAGE Gel picture of fractions of -7S. The fractions collected of the 
sizing column were run on the gel. 
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                 S      Top Solution                 S     Bottom Solution
!Figure 11. SDS PAGE Gel picture of concentrated -7S. The ‘M’ stand for the molecular Marker, the ‘S’ stands for wild-type recombinant HBeAg, the ‘Top solution’ is 
the solution which  retained on the concentrator and the ‘Bottom solution’ is  the solution 
passed through the ultra filter. The top as well as bottom solutions were loaded in 
increasing concentrations in different wells.
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The -7S A plasmid was electroporated in to top10 electro-competent cells.  A 
three liter culture was grown and the protein was purified. The gels below shows the 
various stages of purification.
               M     S       Lys          SN                 S        AS Pellet                 AS SN
!Figure 12. SDS PAGE Gel picture of -7S A. ‘M’ stands for Molecular Marker, ‘S’ stands for wild-type recombinant HBeAg, ‘Lys’ stands for Lysate, ‘SN’ stands for supernatant, ‘AS Pellet’ stands for 20% ammonium sulfate pellet and ‘AS SN’ stands for 20% ammonium sulfate supernatant.
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                 S     7     9    10    11    12    14    16    17    18    20   21    22    23  24
!
Figure 13. SDS PAGE Gel picture of fractions of -7S A. The fractions collected of the 
sizing column were run on the gel. 
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                                               S     Top Sol.    Bottom Sol. 
!Figure 14. SDS PAGE Gel picture of concentrated -7S A. The ‘S’ stands for the wild 
type, the ‘Top solution’ is  the solution which  retained on the concentrator and the 
‘Bottom solution’ is the solution passed through the ultra filter. The top as well as bottom 
solutions were loaded in increasing concentrations in different wells.
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The -7S B plasmid was electroporated in to top10 electro-competent cells.  A 
three liter culture was grown and the protein was  purified. The gel below shows the 
various stages of purification.
              M      S           Lys                              S       AS Pellet            AS SN
!Figure 15. SDS PAGE Gel picture of -7S B. ‘M’ stands for Molecular Marker, ‘S’ stands 
for wild-type recombinant HBeAg, ‘Lys’ stands for Lysate, ‘AS Pellet’ stands for 20% 
ammonium sulfate pellet and ‘AS SN’ stands for 20% ammonium sulfate supernatant.
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               S      7     9    10    11     12    14    16    17   18    20   21    22    23  24
!Figure 16. SDS PAGE Gel picture of fractions of -7S B. The fractions collected of the 
sizing column were run on the gel. 
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                                S          Top Solution              Bottom Solution
!Figure 17. SDS PAGE Gel picture of concentrated -7S B. The ‘S’ stands for the wild type, the ‘Top solution’ is  the solution which  retained on the concentrator and the ‘Bottom solution’ is the solution passed through the ultra filter. The top as well as bottom 
solutions were loaded in increasing concentrations in different wells.
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The -7S C plasmid was electroporated in to TB1 electro-competent cells.  A three 
liter culture was grown and the protein was purified. The gel below shows the various 
stages of purification.
                    S        Lys            SN                   S    AS Pellet    AS SN
!Figure 18. SDS PAGE Gel picture of -7S C. ‘S’ stands  for wild-type recombinant 
HBeAg, ‘Lys’ stands for Lysate, ‘SN’ stands for supernatant, ‘AS Pellet’ stands for 20% 
ammonium sulfate pellet and ‘AS SN’ stands for 20% ammonium sulfate supernatant.
46
                  S      7     9    10    11   12    14    16    17   18    20   21    22    23  24!
Figure 19. SDS PAGE Gel picture of fractions of -7S C. The fractions collected of the 
sizing column were run on the gel. 
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                                                     S        Top Solution                 
!
Figure 20. SDS PAGE Gel picture of concentrated -7S C. ‘S’ stands for wild-type 
recombinant HBeAg, the ‘Top solution’ is  the solution which  retained in the 
concentrator. The top as well as bottom solutions were loaded in increasing 
concentrations in different wells.
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The PCA plasmid was  electroporated in to TB1 electro-competent cells.  A three 
liter culture was grown and the protein was purified. The gel below shows the various 
stages of purification.
                  M     S       Lys           SN                S       AS Pellet            AS SN
!Figure 21. SDS PAGE Gel picture of PCA. ‘M’ stands for Molecular Marker, ‘S’ stands for wild-type recombinant HBeAg, ‘Lys’ stands for Lysate, ‘SN’ stands for supernatant, 
‘AS Pellet’ stands for 20% ammonium sulfate pellet and ‘AS SN’ stands for 20% 
ammonium sulfate supernatant.
49
                    S     7     9    10    11   12   14   16    17   18    20   21   22   23   24
!
Figure 22. SDS PAGE Gel picture of fractions of PCA. The fractions collected of the 
sizing column were run on the gel. 
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                                                 M      S    Top Sol.   Bottom Sol.
!
Figure 23. SDS PAGE Gel picture of concentrated PCA. The ‘M’ stand for the 
molecular Marker, the ‘S’ stands for wild-type recombinant HBeAg, the ‘Top solution’ is 
the solution which  retained on the concentrator and the ‘Bottom solution’ is  the solution 
passed through the ultra filter. The top as well as bottom solutions were loaded in 
increasing concentrations in different wells.
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The PCB plasmid was electroporated in to TB1 electro-competent cells.  A three 
liter culture was grown and the protein was purified. The gel below shows the various 
stages of purification.
                M    S        Lys          SN                S      AS Pellet           AS SN
!Figure 24. SDS PAGE Gel picture of PCB. ‘M’ stands for Molecular Marker, ‘S’ stands 
for wild-type recombinant HBeAg, ‘Lys’ stands for Lysate, ‘SN’ stands for supernatant, 
‘AS Pellet’ stands for 20% ammonium sulfate pellet and ‘AS SN’ stands for 20% 
ammonium sulfate supernatant.
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                  S     7     9    10    11    12    14   16   17    18    20   21    22    23  24
!
Figure 25. SDS PAGE Gel picture of fractions of PCB. The fractions collected of the 
sizing column were run on the gel. 
53
                                             S      Top Sol.     Bottom Sol.
!
Figure 26. SDS PAGE Gel picture of concentrated PCB. ‘S’ stands for wild-type 
recombinant HBeAg, the ‘Top solution’ is the solution which  retained on the 
concentrator and the ‘Bottom solution’ is the solution passed through the ultra filter. The 
top as well as bottom solutions were loaded in increasing concentrations in different 
wells.
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The PCC plasmid was electroporated in to TB1 electro-competent cells.  A three 
liter culture was grown and the protein was purified. The gel below shows the various 
stages of purification.
                                        S      Lys   SN   AS Pellet   AS SN
!
Figure 27. SDS PAGE Gel picture of PCC. ‘M’ stands for Molecular Marker, ‘S’ stands 
for wild-type recombinant HBeAg, ‘Lys’ stands for Lysate, ‘SN’ stands for supernatant, 
‘AS Pellet’ stands for 20% ammonium sulfate pellet and ‘AS SN’ stands for 20% 
ammonium sulfate supernatant.
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                 S      7     9    10    11   12    14    16    17   18    20   21    22    23  24
!Figure 28. SDS PAGE Gel picture of fractions of PCC. The fractions  collected of the sizing column were run on the gel. 
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                    S      T op Solution                 S        Bottom Solution
!Figure 29. SDS PAGE Gel picture of concentrated PCC. ‘S’ stands for wild-type recombinant HBeAg, the ‘Top solution’ is the solution which  retained on the concentrator and the ‘Bottom solution’ is the solution passed through the ultra filter. The top as well as bottom solutions were loaded in increasing concentrations in different 
wells.
An important aspect to be noted here is  that the expression levels of the wild-
type recombinant HBeAg as well as all the mutants differed up to a certain extent. The 
following is the table showing the differences in total concentrations obtained amongst 
the mutants from a 3 liter batch.
These wild-type recombinant HBeAg, -7S, -7S A, -7S B, -7S C, PCA, PCB and 
PCC were stored at concentrations of 1.6mg, 0.98mg, 0.85mg, 1.1mg, 0.9mg, 1mg and 
1.3mg in 1ml buffer respectively at 20℃ until use.  
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Protein Total Amount
   E Antigen 12.8 mg
      -7S 9.1 mg
     -7S A 7.8 mg
    -7S B 5.95 mg
    -7S C 7.7 mg
     PCA 6.3 mg
     PCB 7 mg
     PCC 9.1 mg
Table 2. Table showing the total amounts of all the proteins obtained.
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                     M        S           -7S         -7S A        -7S B        PCA        PCB
!Figure 30. SDS PAGE Gel showing same concentration of proteins loaded. The first lane is the molecular marker followed by 2 lanes each of the wild-type recombinant 
HBeAg, -7S, -7S A, -7S B, PCA and PCB respectively.
From the above gel, it is clear that some mutants are more pure than others and 
they also differ in total concentration. Here equal concentration of all the mutants along 
with the wild-type HBeAg were loaded on an SDS PAGE gel. Two wells for each of the 
mutants  and wild-type were loaded. From the gel it can be observed that the purity of 
the -7S mutant is the highest. It was  almost 100% pure, but it had the lowest 
concentration. On the other hand, the wild-type HBeAg had the highest amounts of 
impurities and it was about 85% pure. Further, mutants  -7S A and -7S B were around 
95% pure whereas, mutants PCA and PCB were about 90% pure.
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Evaluation of the Disulfide Bonding in HBeAg by 2D SDS PAGE
2D gel electrophoresis  was  used to determine the size distribution of the disulfide 
bonded components of wild type recombinant HBeAg. Two 12% gels were made. One 
gel was run with the wild-type recombinant HBeAg in the reduced form as  well as 
multiple lanes of the non-reduced form. After the gel was run, one unstained lane of 
unreduced protein was cut from the gel. The remainder of the gel was stained to verify 
that the resolution of proteins was good. This strip containing the unreduced protein was 
placed horizontally on the top of another 12% gel. A  2% agarose solution was prepared 
containing β-mercaptoethanol and was added to the horizontally placed gel strip, 
completely immersing it. This was allowed to stand for 30 minutes in order to reduce the 
proteins in the strip. In addition to this strip, two lanes were provided in the second gel. 
One was  used for molecular weight markers, and the second was used for fully reduced 
HBeAg. Electrophoresis was then performed as usual. This gel was then silver stained 
so even the small amounts of proteins  on the gel could be seen. The following is  the 
diagrammatic representation.
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Figure 31. 2-D gel (non-reduced followed by reducing conditions) of recombinant 
HBeAg. The proteins  enclosed in the red box are the wild-type recombinant HBeAg 
protein. The protein in the black box is the wild-type recombinant HBeAg which migrates 
faster than monomers under non-reducing condition. The yellow diagonal shows 
proteins whose migration is unaffected by reduction.  
The gel shown above is quite informative concerning the nature of the disulfide 
bonding within the wild-type recombinant HBeAg. Proteins that migrate with the same 
apparent molecular weight under reducing and non reducing conditions should be 
present along the diagonal line indicated in the figure (yellow line). However, it is  clear 
that the HBeAg does not fall on this diagonal, but rather occurs at positions shown 
within the red box. This is the expected result if most of the protein was  present in 
disulfide bonded oligomers greater than dimeric forms. In fact, as can be seen from the 
silver stained gel, the non-reduced strip which was cut out had the wild-type 
recombinant HBeAg throughout the whole strip. Based on this we would conclude that 
the wild-type recombinant HBeAg is present in forms ranging from monomers  to 
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oligomers of increasing size, held together by disulfide bonds. In addition, one species 
appears to be present that runs faster than monomers,  (denoted by the black box in the 
above figure) as evidenced by it position to the left of the diagonal. This would be 
expected to be a monomer with an intra-molecular disulfide bond, creating a less 
completely unfolded, and therefore more compact form of the protein. Upon reduction, 
this  protein is then completely unfolded, and then migrates at the same position as 
expected for monomers (within the red box in the figure). Thus based on this  figure, we 
would conclude that in addition to inter-molecular disulfide bonds, some of the protein 
has at least one intra-molecular disulfide bond.  
ELISA
The antigenic activities of the wild type as well as  all the mutants were checked. 
An ELISA plate was taken wherein the 1st and the 2nd wells  were the controls without 
any protein added to it. The 6th well had the highest amount of protein and it was 
serially diluted up to the 3rd well. Assays were done in triplicates for each of the proteins 
and the results plotted along with standard error indicated.
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The concentration of the wild-type recombinant HBeAg stock solution used for 
the ELISA was 1.6mg/ml. Out of the stock solution 14µg/10µl was taken for the assay.
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Figure 32. Graph showing antigenic activity for wild-type recombinant HBeAg. 
Well number 1 and 2 are the controls  and contain no protein. Well number 6 contains 
the highest amount of protein and it is further serially diluted up to well 3. The dilution 
factor from well 6 to well 3 is 1:10, 1:100, 1:1000, 1:10000 respectively. The dotted lines 
are the error bars.
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The concentration of -7S stock solution used for the ELISA was 1.3mg/ml. Out of 
the stock solution 17µg/10µl was taken for the assay.
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Figure 33. Graph showing antigenic activity for -7S. Well number 1 and 2 are the 
controls and contain no protein. Well number 6 contains the highest amount of protein 
and it is  further serially diluted up to well 3. The dilution factor from well 6 to well 3 is 
1:10, 1:100, 1:1000, 1:10000 respectively. The dotted lines are the error bars.
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The concentration of -7S A stock solution used for the ELISA was 0.98mg/ml. Out 
of the stock solution 9.8µg/10µl was taken for the assay.
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Figure 34. Graph showing antigenic activity for -7S A. Well number 1 and 2 are the 
controls and contain no protein. Well number 6 contains the highest amount of protein 
and it is  further serially diluted up to well 3. The dilution factor from well 6 to well 3 is 
1:10, 1:100, 1:1000, 1:10000 respectively. The dotted lines are the error bars.
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The concentration of -7S B stock solution used for the ELISA was 0.85mg/ml. 
Out of the stock solution 8.5µg/10µl was taken for the assay.
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Figure 35. Graph showing antigenic activity for -7S B. Well number 1 and 2 are the 
controls and contain no protein. Well number 6 contains the highest amount of protein 
and it is  further serially diluted up to well 3. The dilution factor from well 6 to well 3 is 
1:10, 1:100, 1:1000, 1:10000 respectively. The dotted lines are the error bars.
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The concentration of -7S C stock solution used for the ELISA was 1.1mg/ml. Out 
of the stock solution 11µg/10µl was taken for the assay.
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Figure 36. Graph showing antigenic activity for -7S C. Well number 1 and 2 are the 
controls and contain no protein. Well number 6 contains the highest amount of protein 
and it is  further serially diluted up to well 3. The dilution factor from well 6 to well 3 is 
1:10, 1:100, 1:1000, 1:10000 respectively. The dotted lines are the error bars.
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The concentration of PCA stock solution used for the ELISA was 0.9mg/ml. Out 
of the stock solution 9µg/10µl was taken for the assay.
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Figure 37. Graph showing antigenic activity for PCA. Well number 1 and 2 are the 
controls and contain no protein. Well number 6 contains the highest amount of protein 
and it is  further serially diluted up to well 3. The dilution factor from well 6 to well 3 is 
1:10, 1:100, 1:1000, 1:10000 respectively. The dotted lines are the error bars.
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The concentration of PCB stock solution used for the ELISA was 1mg/ml. Out of 
the stock solution 10µg/10µl was taken for the assay.
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Figure 38. Graph showing antigenic activity for PCB. Well number 1 and 2 are the 
controls and contain no protein. Well number 6 contains the highest amount of protein 
and it is  further serially diluted up to well 3. The dilution factor from well 6 to well 3 is 
1:10, 1:100, 1:1000, 1:10000 respectively. The dotted lines are the error bars.
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The concentration of PCC stock solution used for the ELISA was 1.3mg/ml. Out 
of the stock solution 13µg/10µl was taken for the assay.
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Figure 39. Graph showing antigenic activity for PCC. Well number 1 and 2 are the 
controls and contain no protein. Well number 6 contains the highest amount of protein 
and it is  further serially diluted up to well 3. The dilution factor from well 6 to well 3 is 
1:10, 1:100, 1:1000, 1:10000 respectively. The dotted lines are the error bars.
From all of the above assays we would conclude that all of the proteins  exhibited 
high reactivity with the polyclonal antibodies  used in these assays. There are variations 
observed amongst the proteins, however much of these variations are due to the 
differences in the amounts of protein used for the assay. The variations also could be 
due to some differences  in the purity of the proteins.  Whether there are real differences 
in the antigenic activity is  difficult to determine using this polyclonal antibody.  It would 
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be necessary to perform more assays with lower dilution factors to really quantitate the 
immunogenicity. Moreover, the use of more defined monoclonal antibodies would permit 
more definitive conclusions concerning the nature of the antigenicity. However, for the 
current studies, it is sufficient to be able to conclude that the isolated proteins do have 
high antigenic activity.
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Reduction or Reduction and Alkylation of HBeAg
Two gels were run for the wild-type recombinant HBeAg and other mutants, one 
gel was run with samples that had only been reduced, and the other was run with 
samples that had been reduced and alkylated using iodoacetamide. In all of the 
following gels, lane 1 contains  the highest amount of reducing agent. The reducing 
agent in the following lanes is then serially diluted and the last lane contains no 
reducing agent.
Wild-type recombinant HBeAg:
                M    1     2     3      4      5     6      7      8      9     10    11   12    13    14   
Figure 40. Effect of decreasing the concentration of reducing agent on wild-type 
recombinant HBeAg without iodoacetamide treatment. Lane 1 contains the highest 
amount of reducing agent. The reducing agent in the following lanes is then serially 
diluted and the lane 14 contains no reducing agent.
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In the gel shown above, one can see that under fully reduced conditions, the 
protein runs as the expected monomer (indicated by the red box). Under decreasing 
levels  of reducing agent, the amount of monomer decreases. This is  accompanied by 
an increase in the dimeric species observed (as indicated in the blue box above) and 
the appearance of a band that moves faster than monomers. (as shown in the black box 
above).  This is  consistent with the observations on the previous 2D gel. In addition 
there is a minor contaminant protein shown in the yellow box.
On the gel shown below, where the proteins were reduced and alkylated prior to 
being run on the SDS gel, the results are somewhat different.  It is  now clear that the 
majority of the protein fails to enter the gel, (as  indicated in the black box) but rather 
remains in the sample well, because it is too large. We would conclude from this that 
the wild-type recombinant HBeAg is present mostly as a highly disulfide cross-linked 
macromolecular structure.
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Figure 41. Effect of decreasing the concentration of reducing agent on wild-type 
recombinant HBeAg with iodoacetamide treatment. Lane 1 contains the highest 
amount of reducing agent. The reducing agent in the following lanes is then serially 
diluted and the lane 14 contains no reducing agent.
The model shown below would account for these observations. Disulfide bonding 
between cysteines within the core antigen sequence (residues 48 and 61) are known to 
disulfide bond as shown. If the -7C of the pre-core were to form additional disulfide 
bonds as shown, the result would be a high molecular weight oligomeric structure.
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Figure 42. Inter-molecular disulfide bond formation observed from figure 41.
As can be seen from figure 41 that as the concentration of reducing agent 
decreases from left to right, the band at the bottom of the gel disappears showing that 
there are no monomers. Moreover, with decreasing concentration of reducing agent, the 
wild-type recombinant HBeAg mostly stays on top on the wells  since probably it is too 
large to enter the gel. Therefore, it is  possible that a chain is formed connecting a lot of 
particles together.
75
The gel below shows the results of similar studies with the -7S protein. In both 
cases, reduced or reduced and alkylated, the results  do not show the presence of such 
highly cross-linked protein. This is most readily seen in the reduced and alkylated 
samples.  
                   M    1     2     3     4      5     6     7      8      9    10    11  12   13   14
!
Figure 43. Effect of decreasing the concentration of reducing agent on -7S 
without iodoacetamide treatment. Lane 1 contains the highest amount of reducing 
agent. The reducing agent in the following lanes is  then serially diluted and the lane 14 
contains no reducing agent.
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Figure 44. Effect of decreasing the concentration of reducing agent on -7S  with 
iodoacetamide treatment. Lane 1 contains  the highest amount of reducing agent. The 
reducing agent in the following lanes is then serially diluted and the lane 14 contains no 
reducing agent.
As can be seen in the above gel, there is no evidence for protein that does not 
enter the gel (the black box) but rather the protein is present as mostly di-mers (cyan 
box) with some monomers as well (red box). The model shown below would be 
consistent with these results.
77
Figure 45. Inter-molecular disulfide bond formation observed from figure 44
It can be observed from figure 44 that with decreasing concentration of reducing 
agent from left to right, monomers as well as  di-mers are formed. The di-mers  (the band 
at the center of the gel) are possible due to inter-molecular disulfide bond formation 
between the cysteine at 61 of identical monomers (7). Some of them might not form the 
inter-molecular disulfide bonds leading to the formation of monomers (The band at the 
bottom of the gel). Moreover, there is no protein observed on top of the wells as could 
be seen in wild-type recombinant HBeAg. This must be because the cysteine at -7, 
which is  responsible for formation of inter chain disulfide bonds between dimers has 
been replaced by serine. 
78
-7S A and -7S B:
                M     1     2      3     4      5      6       7     8      9     10    11    12   13   14
!Figure 46. Effect of decreasing the concentration of reducing agent on -7S A 
without iodoacetamide treatment. Lane 1 contains the highest amount of reducing 
agent. The reducing agent in the following lanes is  then serially diluted and the lane 14 
contains no reducing agent.
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Figure 47. Effect of decreasing the concentration of reducing agent on -7S A 
with iodoacetamide. treatment. Lane 1 contains the highest amount of reducing 
agent. The reducing agent in the following lanes is  then serially diluted and the lane 14 
contains no reducing agent.
As can be seen in the above gel, there is no evidence for protein that does not 
enter the gel (cyan box) but rather the protein is  present as mostly di-mers  (red box) 
with very few monomers as  well (black box). The model shown below would be 
consistent with these results.
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Figure 48. Inter-molecular disulfide bond formation observed from figure 47
               M     1      2     3     4      5      6      7      8     9     10    11    12   13   14
!Figure 49. Effect of decreasing the concentration of reducing agent on -7S B without iodoacetamide treatment. Lane 1 contains the highest amount of reducing agent. The reducing agent in the following lanes is  then serially diluted and the lane 14 
contains no reducing agent.
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!Figure 50. Effect of decreasing the concentration of reducing agent on -7S B with iodoacetamide treatment. Lane 1 contains the highest amount of reducing agent. The reducing agent in the following lanes is then serially diluted and the lane 14 
contains no reducing agent.
From the above gel, the same is  the conclusion as obtained in mutant -7S A. 
There is no evidence of protein not entering the gel and moreover there is formation of 
di-mers as well as very few monomers.
The following is the model shown bellow which is consistent with the results.
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Figure 51. Inter-molecular disulfide bond formation observed from figure 50
It can be observed from figures 47 and 50 that with the decreasing concentration 
of reducing agent from left to right, there is majorly di-mer formation and very little 
monomer formation. The di-mer formation in figure 47 is  due to inter-molecular disulfide 
linkage between cysteine at 61 of two identical monomers, since the cysteine at 48 is 
mutated in this  mutant. Whereas, the di-mer formation in figure 50 is due to inter-
molecular disulfide linkage between cysteine at 48 of two identical monomers, since the 
cysteine at 61 is mutated in this mutant. These are the same results as obtained by Jian 
Zheng and his group (5). Though they got these results on truncated HBcAg, the 
sequence for the truncated HBcAg and HBeAg is  almost identical. Moreover, the 
cysteine at -7 is mutated in both the mutants and so no staining is observed on the top 
of the wells in both figures 47 as well as  50. This indicated that there are no high 
molecular weight cross-linked aggregates formed.
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-7S C and PCC:
              M     1      2      3      4      5       6       7      8      9     10     11    12    13   
Figure 52. Effect of decreasing the concentration of reducing agent on -7S C with 
iodoacetamide treatment. Lane 1 contains  the highest amount of reducing agent. The 
reducing agent in the following lanes is then serially diluted and the lane 14 contains no 
reducing agent.
The results  obtained in the above mutant -7S C were not consistent with our 
hypothesis as  we just saw formation of monomers  (black box). We expected to see 
formation of di-mers  as the concentration of reducing agent decreased but that did not 
occur. Thus, the -7S C did not give consistent results.
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Figure 53. Effect of decreasing the concentration of reducing agent on PCC 
with iodoacetamide treatment. Lane 1 contains the highest amount of reducing agent. 
The reducing agent in the following lanes is then serially diluted and the lane 14 
contains no reducing agent.
As can be seen from the above gel, the results obtained where consistent for this 
mutant. We saw di-mer formation (black box) and formation of monomers (red box) 
whereas formation of the fast moving band disappeared suggesting that the intra-
molecular bond is between the cysteine at -7 and the cysteine at 107.
The following are the models consistent with the results.
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Figure 54. Inter-molecular disulfide bond formation observed from figure 53.
Figure 55. Disulfide bond formation observed from figure 53.
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The results  obtained in figure 52 were not as expected. We expected -7S C to 
give the same results as  the PCC mutant. The PCC mutant just had the cysteine at 107 
mutated whereas the -7S C had the cysteine at -7 mutated along with the cysteine at 
107. Thus, both the mutants would prevent formation of the intra-molecular disulfide 
bonds. We still expected the presence of di-mers as the concentration of reducing agent 
decreased because the cysteine at 48 and 61 were present. But we only obtained 
monomers for the -7S C mutant. So this was not consistent with what results we had 
obtained so far.
Moreover, figure 53 gave consistent results. As the concentration of reducing 
agent was decreased from left to right, di-mer formation was observed along with 
formation of monomers but the formation of the band due to intra-molecular disulfide 
bond (from result below) had disappeared thus, indicating that cysteine at 107 was 
involved in making intra-molecular disulfide bonds with cysteine at position -7. 
Furthermore, the di-mers were still formed since both cysteine at 48 and cysteine at 61 
were present in this mutant.
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PCA and PCB:
                 M     1     2      3     4     5      6      7     8     9     10   11   12   13   14
Figure 56. Effect of decreasing the concentration of reducing agent on PCA 
without iodoacetamide treatment. Lane 1 contains the highest amount of reducing 
agent. The reducing agent in the following lanes is  then serially diluted and the lane 14 
contains no reducing agent.
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Figure 57. Effect of decreasing the concentration of reducing agent on PCA 
with iodoacetamide treatment. Lane 1 contains the highest amount of reducing agent. 
The reducing agent in the following lanes is then serially diluted and the lane 14 
contains no reducing agent.
As can be seen from the above gels, there is di-mer formation (black arrow) 
along with monomer formation (red arrow). But here there is  also the formation of the 
fast moving band (cyan arrow) which is caused due to intra-molecular disulfide bond 
formation.
The following are the models that are consistent to the results.
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Figure 58. Inter-molecular disulfide bond formation observed from figure 57.
Figure 59. Intra-molecular disulfide bond formation observed from figure 57.
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Figure 60. Effect of decreasing the concentration of reducing agent on PCB 
without iodoacetamide treatment. Lane 1 contains the highest amount of reducing 
agent. The reducing agent in the following lanes is  then serially diluted and the lane 14 
contains no reducing agent.
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Figure 61. Effect of decreasing the concentration of reducing agent on PCB 
with iodoacetamide treatment. Lane 1 contains the highest amount of reducing agent. 
The reducing agent in the following lanes is then serially diluted and the lane 14 
contains no reducing agent.
As can be observed from the above gels, the results  are consistent with the PCA 
mutant. There is formation of di-mers (black arrow) along with formation of monomers 
(red arrow) and also the fast moving band (cyan arrow) is seen.
The following are the models consistent to the results.
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Figure 62. Inter-molecular disulfide bond formation observed from figure 61.
Figure 63. Intra-molecular disulfide bond formation observed from figure 61.
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It can be observed from figures 57 and 61 that with decreasing concentrations of 
reducing agent from left to right, there is formation of di-mers as well as monomers. The 
important part to be observed here is the presence of two bands at the bottom of the 
gel. The second band from the bottom is  due to monomers whereas, the first band from 
the bottom might be due to intra-molecular disulfide bond formation as mentioned by 
Wasenauer and group (7). According to the results obtained from figure 57, the intra-
molecular disulfide bond is between the cysteine at position -7 and the cysteine at 
position 107. This can be predicted because in both the mutants, there has been no 
mutations at position cysteine -7 and cysteine 107. Moreover, in mutants with mutation 
at cysteine -7 and cysteine 107, these bottom bands  were not obtained. Further, the di-
mer formation here is again due to inter-molecular disulfide bond formation between the 
cysteine at 61 and cysteine at 48 of two identical monomers.
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Quantitation of Sulfhydryl Groups
The standard cysteine curve was first plotted to check if the line passed through 
zero and gave a linear relationship between absorbance and cysteine concentration.
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Figure 64. Cysteine Standard Curve. The tubes containing 10µM, 20µM, 30µM, 40µM, 
50µM, 70µM and 100µM of cysteine stock solution were reacted with Ellman’s reagent 
and their absorbance readings were taken at 412nm. These values were plotted to 
obtain the cysteine standard curve.
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The following is the table showing the absorbances obtained at 412nm and the 
moles of -SH/Mole of protein for all the mutants.
SDS Treated Moles of -SH/
Mole of Protein
Non - SDS Moles of -SH/
Mole of Protein
HBeAg 0.333 0.5 0.231 0.3
-7S 0.206 0.3 0.151 0.25
-7S A 0.256 0.5 0.221 0.4
-7S B 0.344 0.57 0.190 0.3
-7S C 0.351 0.6 0.341 0.55
PCA 0.310 0.5 0.184 0.25
PCB 0.346 0.57 0.153 0.25
PCC 0.367 0.57 0.326 0.55
Table 3. Spectrophotometer readings at 412nm along with the moles of -SH/ Mole 
of proteins.
From the above values for the native as well as the mutant proteins, it was 
observed that approximately 0.5 cysteine residues were always present as free 
sulfhydryl. Jian Zheng and his  group had stated that the cysteine at 107 was always 
free in truncated HBcAg (5). The sequence of the truncated HBcAg is almost identical to 
HBeAg. At first on treating the HBeAg with Ellman’s reagent, we obtained almost no free 
cysteine for most of the mutants, but on treating the sample with 0.1% SDS, half 
cysteine was obtained as free. This half cysteine might be due to the cysteine at 107 
which is sometimes free and sometimes is involved in an intra-molecular disulfide bond 
with cysteine at -7 or may be due to several of the cysteines being partially unpaired. In 
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any case, since the protein has 4 cysteines it is clear that they are almost all involved in 
disulfide bonding. Moreover, since all mutations do not increase the content of free 
cysteine, each of the cysteines must pair only between identical residues (-7 to -7, 48 to 
48, 61 to 61). If, for example cysteine 48 were disulfide bonded to cysteine 61, then 
mutation of cysteine 48 would lead to a free sulfhydryl for cysteine 61. Since the 
samples had to be treated with 0.1% SDS to react maximally, this suggests that some of 
the cysteines are buried and therefore are not able to react with the Ellman’s  reagent. 
Also, from previous research work (5) regarding core structure it can be said that the 
cysteine at 48 is also not always involved in making inter-molecular disulfide bonds 
between cysteine at 48 of two identical monomers. Therefore, we can conclude from 
mutants  -7S, -7S B, -7S C, PCB and PCC that in HBeAg, the half free cysteine may 
sometimes also be due to the cysteine at 48 which might not always be involved in 
inter-molecular disulfide bonding. This  is because all the mutants  have the Cys at 48 
unmutated.
To further check if the cysteine disulfide bonds were exposed on surface or not 
for reduction, the ReduceIM column was used. It was observed that on passing the 
protein through this  column, it was not reduced indicating that all the cysteine disulfide 
bonds were buried and none of them were exposed on the surface (Results not shown).
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Circular Dichroism Spectra of the Recombinant HBeAg and its Mutants
Figure 65. Circular dichroism of all the proteins.
The circular dichroism spectra of each of the proteins  was determined.  Since 
these proteins differ only by conservative point mutations and because the proteins 
behaved identically during purification, we were not expecting to find any gross 
differences in the secondary structures between the mutants and the wild type. 
However, from the data we obtained in figure 65, we cannot rule out that there are some 
differences. The spectra appeared to fall into two groups that had some differences in 
the secondary structures between them. The E antigen, -7S A, -7S B and -7S C was 
one group that had almost similar secondary structures and on the other hand -7S, 
PCA, PCB and PCC was  the other group that had almost similar secondary structures. 
However, due to differences in purity and difficulty in quantitating the protein 
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concentration due to differences in the A280 caused by light scattering, we would not 
conclude that these differences are real.
Light Scattering
Dynamic light scattering measurements  were made on each of the proteins to 
examine the molecular size. The following are the results  obtained. From the results  it 
can be concluded that all of the proteins assemble into a particulate form, although the 
sizes do vary. The particle sizes ranged from 30nm - 43nm.
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The following are the results obtained for wild-type recombinant HBeAg.
Figure 66. Light scatter data showing particle size of wild-type recombinant 
HBeAg.
Figure 67. Graph showing 10 data points obtained for wild-type recombinant 
HBeAg
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The following are the results obtained for -7S.
Figure 68. Light scatter data showing particle size of -7S.
Figure 69. Graph showing 10 data points obtained for -7S.
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The following are the results obtained for -7S A.
Figure 70. Light scatter data showing particle size of -7S A.
Figure 71. Graph showing 10 data points obtained for -7S A.
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The following are the results obtained for -7S B.
Figure 72. Light scatter data showing particle size of -7S B.
Figure 73. Graph showing 10 data points obtained for -7S B.
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The following are the results obtained for -7S C.
Figure 74. Light scatter data showing particle size of -7S C.
Figure 75. Graph showing 10 data points obtained for -7S C.
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The following are the results obtained for PCA.
Figure 76. Light scatter data showing particle size of PCA.
Figure 77. Graph showing 10 data points obtained for PCA.
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The following are the results obtained for PCB.
Figure 78. Light scatter data showing particle size of PCB.
Figure 79. Graph showing 10 data points obtained for PCB.
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The following are the results obtained for PCC.
Figure 80. Light scatter data showing particle size of PCC.
Figure 81. Graph showing 10 data points obtained for PCC.
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Chapter 6: Conclusions
At the outset, it can be noted from our data that the expression levels of the wild 
type as well as the mutants varied. The variations were not on a large scale but one 
would not expect such variations  in expression levels since the only change between 
the mutants was a cysteine substituted to a serine. Further, the purity levels  also varied 
due to the differences in expression levels, but for most part, these variations in 
concentration and purity between the mutants did not affect our conclusions.
The ELISA data showed that all the mutants as well as the wild type had high 
antigenicity. The antigenicity did vary somewhat, and this could be due to the variation 
in concentrations of the mutants. This was because the absorbance at 280 nm was 
used to determine the concentrations of all the proteins.  It is important to note here that 
the percentage purity of all the proteins was not the same and so when the absorbance 
at 280nm was taken for the proteins, the impurities present along with the proteins also 
got measured. Thus, the concentrations obtained were not only the concentration of our 
protein but it also included the other proteins (impurities) which were present in the 
solution in minute amounts. Due to this reason we saw some variations in the 
antigenicity but from the ELISA we can conclude that all the mutants  did have antigenic 
activity.
Moreover, light scattering results obtained showed that all the proteins 
assembled in to particulate antigens and the size of all the proteins varied from 30 to 43 
nanometers. This  result is  consistent with their elution from Sepharose CL4B, which has 
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an exclusion limit of about 10 million, and the antigen eluted after the void volume, but 
well before low molecular weight proteins were eluted.
The circular dichroism data showed that all the mutants had a high alpha helix 
content. There may be differences, but due to the differences in purity of the proteins, it 
was not possible to conclude that the differences observed in the CD spectra represent 
true differences. It could also be observed from the CD spectra of the mutants that the 
proteins fell into two groups that had some differences in the secondary structures 
between them. The E antigen, -7S A, -7S B and -7S C was one group that had almost 
similar CD spectra and on the other hand -7S, PCA, PCB and PCC was the other group 
that had almost similar CD spectra.  Thus it seems as if the double mutant species may 
have differences from the single mutants.  Before this conclusion could be verified, it 
would have to be shown that the purity of all the proteins was the same, and that the 
protein concentrations used were identical. This, as noted above presents some 
problems that have not yet been resolved.
It has been previously found that there are inter-molecular disulfide bonds in 
HBcAg. The cysteine at 61 was always and the cysteine at 48 was partly involved in 
inter-molecular disulfide bond formation with the identical residue of other monomer. 
The cysteine at 183 was also always involved in inter-molecular disulfide bond 
formation with the identical residue of other monomer (6). Moreover, it was also 
observed that in HBeAg the cysteine at 61 was always  involved in an inter-molecular 
disulfide bond formation with the identical residue of the other monomer (7). Now from 
our studies, the 2D gel electrophoresis  on the E antigen showed that the E antigen was 
present in a range from monomers to oligomers suggesting that there were multiple 
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inter-molecular disulfide bonds. Also, one species of protein was observed on this gel, 
that by its  presence to the left of the diagonal, migrated faster under non-reducing 
conditions than under reducing conditions. This is  what is  expected for proteins that 
have intra-molecular disulfide bonds. From our results obtained by checking the effect 
of decreasing concentration of reducing agent of all the mutants  on SDS PAGE gels  it 
could be concluded that the cysteine at 61 was always and the cysteine at 48 was partly 
involved in inter-molecular disulfide bond formation with the identical residue of other 
monomer resulting in formation of di-mers. Unlike the previously reported results with 
the truncated HBcAg protein, very little of the wild-type HBeAg, under non-reducing 
conditions, even entered the stacking gel on SDS-PAGE.  Thus the wild-type HBeAg 
must be present as a highly cross-linked polymer. However, on mutating the cysteine at 
-7, it was found that there were only presence of di-mers and monomers and the 
oligomers present on top of the wells which could not enter the gel had disappeared. 
Thus this mutant behaved identically to the truncated HBcAg. This leads us  to conclude 
that the cysteine at -7 was involved in the formation of oligomers by forming disulfide 
bonds between the dimers, but that the dimers were held together by the same disulfide 
bonding pattern as had been found for the truncated HBcAg.   Thus, it can be concluded 
that the di-mers  formed by the inter-molecular disulfide bond formation by cysteine at 61 
and 48 were further connected by the cysteine at -7 to form a lattice of protein oligomers 
of increasing sizes. 
Further, from mutants PCA and PCB. a band was  observed below the band 
observed for the monomers at the bottom of the gel, under non-reducing conditions. 
This  band ran faster than the monomers on gel because of intra-molecular disulfide 
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bond formation. It has  been previously concluded that there are intra-molecular disulfide 
bonds formed in HBeAg (7). It had later on been proposed that the intra-molecular 
disulfide bonds were between the cysteine at -7 and the cysteine at 61 (8). According to 
results obtained by us on mutant PCC (mutation of cysteine at 107), it could be 
concluded that the intra-molecular disulfide bond formation was between the cysteine at 
-7 and the cysteine at 107. Also, this intra-molecular disulfide bond formation was  not 
present  in all of the polypeptide chains, since the intensity of the band observed at this 
position was not very intense, thus corresponding to only a small population of this 
species of the protein.
It was further observed that all the disulfide bonds were buried and were not 
available on the surface for reduction. From the analysis using Ellman’s reagent it was 
found that in HBeAg, approximately one-half of a cysteine was always  present as  the 
free sulfhydryl. It had been previously found that cysteine at position 107 was  always 
free in HBcAg (6). We think this half free cysteine in HBeAg was either due to the 
cysteine at 107 which was sometimes free and not always involved in intra-molecular 
disulfide bonding or it was due to the cysteine at 48 which was sometimes free and not 
always involved in inter-molecular disulfide bonding.
Thus, from the data presented above we can conclude that the HBeAg was 
present in solution as a homogeneous particulate form of about 36 nm, while the 
mutants  were of similar but not identical size . Although the particles were uniform in 
size, their disulfide bonding pattern differed in a consistent manner.  For the wild-type 
HBeAg:
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1. Small number of free monomers without any disulfide bonds, seen as 
monomers under non-reducing conditions.
2. Small number of monomers with formation of an intra-molecular disulfide bond 
between the cysteine at -7 and cysteine at 107, seen as  more rapidly low molecular 
weight species that migrate more rapidly than monomers, but convert to monomers 
upon reduction.
3. Most of the  monomers cross-linked into polymers of varying lengths  in which 
di-mers were formed by the disulfide bonds between cysteines at 61 and 48, then 
subsequent disulfide bonding between different dimers connected through the cysteine 
at -7.
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Chapter 7: Future Directions
The -7S C mutant did not give the results as  expected. We expected that since 
the -7S C mutant had a mutation of the cysteine at position -7 as well as at position 107, 
there would be presence of dimers and the fast moving band due to intra-molecular 
disulfide bond formation would disappear. The formation of di-mers would be due to the 
presence of cysteine at position 48 and 61 whereas the fast moving band which is 
thought to be an intra-molecular disulfide bond formed between cysteine at -7 and 
cysteine at 107 would disappear since both of them were mutated in this mutant. But 
these are not the results what we obtained. We just obtained monomers as the 
concentration of reducing agent decreased on an SDS PAGE gel. These results 
obtained are not consistent with our hypothesis and therefore, further analysis  will have 
to be done to perfectly identify the disulfide bonding pattern.
For this we can carry out HPLC technique along with mass spectroscopy. At first, 
the recombinant HBeAg will have to be digested with an enzyme which is  active at basic 
pH so that the enzyme does not prevent the disulfide bond formation. Once the 
digestion is carried out, the fragments will have to be separated on a C18 column. Once 
the purified fragments are obtained, they can be subjected to mass spectroscopy so 
that we can identify specifically which cysteines are disulfide bonded to which ones.
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